false 2020 Q2 0001227636 --12-31 Accelerated Filer 2025-02-01 P1Y P1Y P1Y P1Y P1Y P1Y P5Y2M12D P3Y9M18D P5Y2M12D P6Y1M6D 0001227636 2020-01-01 2020-06-30 xbrli:shares 0001227636 2020-07-31 iso4217:USD 0001227636 2020-06-30 0001227636 2019-12-31 iso4217:USD xbrli:shares 0001227636 2020-04-01 2020-06-30 0001227636 2019-04-01 2019-06-30 0001227636 2019-01-01 2019-06-30 0001227636 us-gaap:CommonStockMember 2018-12-31 0001227636 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001227636 us-gaap:RetainedEarningsMember 2018-12-31 0001227636 2018-12-31 0001227636 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001227636 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001227636 2019-01-01 2019-03-31 0001227636 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001227636 us-gaap:CommonStockMember 2019-03-31 0001227636 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001227636 us-gaap:RetainedEarningsMember 2019-03-31 0001227636 2019-03-31 0001227636 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001227636 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001227636 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001227636 us-gaap:CommonStockMember 2019-06-30 0001227636 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001227636 us-gaap:RetainedEarningsMember 2019-06-30 0001227636 2019-06-30 0001227636 us-gaap:CommonStockMember 2019-12-31 0001227636 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001227636 us-gaap:RetainedEarningsMember 2019-12-31 0001227636 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001227636 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001227636 2020-01-01 2020-03-31 0001227636 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001227636 us-gaap:CommonStockMember 2020-03-31 0001227636 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001227636 us-gaap:RetainedEarningsMember 2020-03-31 0001227636 2020-03-31 0001227636 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001227636 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001227636 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001227636 us-gaap:CommonStockMember 2020-06-30 0001227636 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001227636 us-gaap:RetainedEarningsMember 2020-06-30 0001227636 country:US 2020-01-01 2020-06-30 0001227636 us-gaap:NonUsMember 2020-01-01 2020-06-30 0001227636 stim:PaycheckProtectionProgramMember stim:SiliconValleyBankMember 2020-04-30 0001227636 2019-01-01 2019-12-31 0001227636 stim:ThirtyFiveMillionCreditFacilityMember stim:OxfordFinanceLimitedLiabilityCompanyMember 2020-06-30 0001227636 stim:ThirtyFiveMillionCreditFacilityMember stim:OxfordFinanceLimitedLiabilityCompanyMember 2020-01-01 2020-06-30 0001227636 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:MoneyMarketFundsMember 2020-06-30 0001227636 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MoneyMarketFundsMember 2020-06-30 0001227636 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2020-06-30 0001227636 us-gaap:MoneyMarketFundsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-12-31 0001227636 us-gaap:MoneyMarketFundsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0001227636 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2019-12-31 0001227636 us-gaap:EquipmentMember 2020-06-30 0001227636 us-gaap:EquipmentMember 2019-12-31 0001227636 us-gaap:OfficeEquipmentMember 2020-06-30 0001227636 us-gaap:OfficeEquipmentMember 2019-12-31 0001227636 us-gaap:ComputerEquipmentMember 2020-06-30 0001227636 us-gaap:ComputerEquipmentMember 2019-12-31 0001227636 us-gaap:ManufacturingFacilityMember 2020-06-30 0001227636 us-gaap:ManufacturingFacilityMember 2019-12-31 0001227636 us-gaap:LeaseholdImprovementsMember 2020-06-30 0001227636 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001227636 us-gaap:EquipmentLeasedToOtherPartyMember 2020-06-30 0001227636 us-gaap:EquipmentLeasedToOtherPartyMember 2019-12-31 0001227636 us-gaap:OtherAssetsMember 2020-06-30 0001227636 us-gaap:OtherAssetsMember 2019-12-31 utr:sqft 0001227636 stim:HeadquartersAndOfficeEquipmentIncludingCopiersMember 2020-06-30 xbrli:pure 0001227636 stim:NeuroStarAdvancedTherapySystemsMember 2020-06-30 0001227636 us-gaap:EquipmentLeasedToOtherPartyMember 2020-04-01 2020-06-30 0001227636 us-gaap:EquipmentLeasedToOtherPartyMember 2019-04-01 2019-06-30 0001227636 us-gaap:EquipmentLeasedToOtherPartyMember 2020-01-01 2020-06-30 0001227636 us-gaap:EquipmentLeasedToOtherPartyMember 2019-01-01 2019-06-30 0001227636 2020-07-01 2020-06-30 0001227636 2021-01-01 2020-06-30 0001227636 2022-01-01 2020-06-30 0001227636 2023-01-01 2020-06-30 0001227636 2024-01-01 2020-06-30 0001227636 2025-01-01 2020-06-30 stim:Customer 0001227636 stim:ThirtyFiveMillionCreditFacilityMember stim:SolarCapitalLtdMember 2017-03-31 0001227636 stim:SolarCapitalLtdMember stim:FiftyMillionCreditFacilityMember 2020-03-02 0001227636 stim:SolarCapitalLtdMember stim:ThirtyFiveMillionCreditFacilityMember stim:TermALoanMember 2020-03-02 0001227636 stim:SolarCapitalLtdMember stim:FifteenMillionCreditFacilityMember stim:TermBLoanMember 2020-03-02 0001227636 stim:SolarCapitalLtdMember stim:FifteenMillionCreditFacilityMember stim:TermBLoanMember 2020-01-01 2020-06-30 0001227636 stim:SolarCapitalLtdMember stim:FiftyMillionCreditFacilityMember stim:TermALoanMember 2020-03-01 2020-03-02 stim:Tranche 0001227636 stim:SolarCapitalLtdMember stim:FiftyMillionCreditFacilityMember 2020-03-01 2020-03-02 0001227636 stim:TermALoanAndTermBLoanMember stim:SolarCapitalLtdMember 2020-03-01 2020-03-02 0001227636 stim:TermALoanAndTermBLoanMember stim:SolarCapitalLtdMember 2020-03-02 stim:Event 0001227636 stim:TermALoanAndTermBLoanMember stim:SolarCapitalLtdMember 2020-01-01 2020-06-30 0001227636 stim:FiftyMillionCreditFacilityMember us-gaap:DebtInstrumentRedemptionPeriodOneMember stim:SolarCapitalLtdMember 2020-03-01 2020-03-02 0001227636 stim:FiftyMillionCreditFacilityMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember stim:SolarCapitalLtdMember 2020-03-01 2020-03-02 0001227636 stim:FiftyMillionCreditFacilityMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember stim:SolarCapitalLtdMember 2020-03-01 2020-03-02 0001227636 stim:OxfordFinanceLimitedLiabilityCompanyMember stim:ThirtyFiveMillionCreditFacilityMember 2020-02-29 0001227636 stim:TermALoanMember stim:OxfordFinanceLimitedLiabilityCompanyMember stim:ThirtyFiveMillionCreditFacilityMember 2020-02-29 0001227636 stim:TermBLoanMember stim:OxfordFinanceLimitedLiabilityCompanyMember stim:ThirtyFiveMillionCreditFacilityMember 2020-02-29 0001227636 stim:TermCLoanMember stim:OxfordFinanceLimitedLiabilityCompanyMember stim:ThirtyFiveMillionCreditFacilityMember 2020-02-29 0001227636 stim:OxfordFinanceLimitedLiabilityCompanyMember us-gaap:LondonInterbankOfferedRateLIBORMember stim:ThirtyFiveMillionCreditFacilityMember 2020-01-01 2020-06-30 0001227636 stim:TermALoanMember stim:ThirtyFiveMillionCreditFacilityMember stim:OxfordFinanceLimitedLiabilityCompanyMember 2020-02-29 2020-02-29 0001227636 stim:TermBLoanMember stim:ThirtyFiveMillionCreditFacilityMember stim:OxfordFinanceLimitedLiabilityCompanyMember 2020-02-29 2020-02-29 0001227636 stim:CommonStockWarrantsMember 2020-06-30 0001227636 stim:CommonStockWarrantsMember 2019-12-31 0001227636 us-gaap:EmployeeStockOptionMember 2020-06-30 0001227636 us-gaap:EmployeeStockOptionMember 2019-12-31 0001227636 us-gaap:RestrictedStockUnitsRSUMember 2020-06-30 0001227636 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001227636 us-gaap:StockCompensationPlanMember 2020-06-30 0001227636 us-gaap:StockCompensationPlanMember 2019-12-31 0001227636 us-gaap:EmployeeStockMember 2020-06-30 0001227636 us-gaap:EmployeeStockMember 2019-12-31 0001227636 stim:ExercisePriceRangeOneMember 2020-06-30 0001227636 stim:ExercisePriceRangeTwoMember 2020-06-30 0001227636 stim:ExercisePriceRangeThreeMember 2020-06-30 0001227636 stim:ExercisePriceRangeFourMember 2020-06-30 0001227636 stim:ExercisePriceRangeFiveMember 2020-06-30 0001227636 stim:ExercisePriceRangeOneMember 2020-01-01 2020-06-30 0001227636 stim:ExercisePriceRangeTwoMember 2020-01-01 2020-06-30 0001227636 stim:ExercisePriceRangeThreeMember 2020-01-01 2020-06-30 0001227636 stim:ExercisePriceRangeFourMember 2020-01-01 2020-06-30 0001227636 stim:ExercisePriceRangeFiveMember 2020-01-01 2020-06-30 0001227636 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001227636 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0001227636 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0001227636 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-06-30 0001227636 stim:CommonStockWarrantsMember 2020-01-01 2020-06-30 0001227636 stim:CommonStockWarrantsMember 2019-01-01 2019-06-30 0001227636 us-gaap:CostOfSalesMember 2020-04-01 2020-06-30 0001227636 us-gaap:CostOfSalesMember 2019-04-01 2019-06-30 0001227636 us-gaap:CostOfSalesMember 2020-01-01 2020-06-30 0001227636 us-gaap:CostOfSalesMember 2019-01-01 2019-06-30 0001227636 us-gaap:SellingAndMarketingExpenseMember 2020-04-01 2020-06-30 0001227636 us-gaap:SellingAndMarketingExpenseMember 2019-04-01 2019-06-30 0001227636 us-gaap:SellingAndMarketingExpenseMember 2020-01-01 2020-06-30 0001227636 us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-06-30 0001227636 us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0001227636 us-gaap:GeneralAndAdministrativeExpenseMember 2019-04-01 2019-06-30 0001227636 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0001227636 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-06-30 0001227636 us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001227636 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0001227636 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0001227636 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0001227636 stim:TwoThousandEighteenEquityIncentivePlanMember srt:MaximumMember 2020-06-30 0001227636 stim:TwoThousandEighteenEquityIncentivePlanMember 2020-01-01 2020-06-30 0001227636 stim:TwoThousandEighteenEquityIncentivePlanMember srt:MaximumMember 2020-01-01 2020-06-30 0001227636 us-gaap:ShareBasedCompensationAwardTrancheOneMember stim:TwoThousandEighteenEquityIncentivePlanMember 2020-01-01 2020-06-30 stim:Installment 0001227636 stim:TwoThousandEighteenEquityIncentivePlanMember 2020-06-30 0001227636 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001227636 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-06-30 0001227636 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0001227636 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0001227636 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0001227636 stim:RestrictedStockAndRestrictedStockUnitsRSUMember 2020-04-01 2020-06-30 0001227636 stim:RestrictedStockAndRestrictedStockUnitsRSUMember 2019-04-01 2019-06-30 0001227636 stim:RestrictedStockAndRestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0001227636 stim:RestrictedStockAndRestrictedStockUnitsRSUMember 2019-01-01 2019-06-30 0001227636 stim:RestrictedStockAndRestrictedStockUnitsRSUMember 2020-06-30 0001227636 stim:FormerChiefExecutiveOfficerMember 2020-04-01 2020-06-30 0001227636 stim:FormerChiefExecutiveOfficerMember 2020-01-01 2020-06-30 stim:Segment 0001227636 country:US us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember 2020-04-01 2020-06-30 0001227636 us-gaap:NonUsMember us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember 2020-04-01 2020-06-30 0001227636 us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember 2020-04-01 2020-06-30 0001227636 country:US us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember 2019-04-01 2019-06-30 0001227636 us-gaap:NonUsMember us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember 2019-04-01 2019-06-30 0001227636 us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember 2019-04-01 2019-06-30 0001227636 stim:ProductCategoryMember country:US us-gaap:SalesRevenueNetMember stim:NeuroStarAdvancedTherapySystemMember 2020-04-01 2020-06-30 0001227636 stim:ProductCategoryMember country:US us-gaap:SalesRevenueNetMember stim:TreatmentSessionsMember 2020-04-01 2020-06-30 0001227636 stim:ProductCategoryMember country:US us-gaap:SalesRevenueNetMember stim:OtherProductMember 2020-04-01 2020-06-30 0001227636 stim:ProductCategoryMember country:US us-gaap:SalesRevenueNetMember 2020-04-01 2020-06-30 0001227636 stim:ProductCategoryMember country:US us-gaap:SalesRevenueNetMember stim:NeuroStarAdvancedTherapySystemMember 2019-04-01 2019-06-30 0001227636 stim:ProductCategoryMember country:US us-gaap:SalesRevenueNetMember stim:TreatmentSessionsMember 2019-04-01 2019-06-30 0001227636 stim:ProductCategoryMember country:US us-gaap:SalesRevenueNetMember stim:OtherProductMember 2019-04-01 2019-06-30 0001227636 stim:ProductCategoryMember country:US us-gaap:SalesRevenueNetMember 2019-04-01 2019-06-30 0001227636 stim:ProductCategoryMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember stim:NeuroStarAdvancedTherapySystemMember 2020-04-01 2020-06-30 0001227636 stim:ProductCategoryMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember stim:TreatmentSessionsMember 2020-04-01 2020-06-30 0001227636 stim:ProductCategoryMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember stim:OtherProductMember 2020-04-01 2020-06-30 0001227636 stim:ProductCategoryMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember 2020-04-01 2020-06-30 0001227636 stim:ProductCategoryMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember stim:NeuroStarAdvancedTherapySystemMember 2019-04-01 2019-06-30 0001227636 stim:ProductCategoryMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember stim:TreatmentSessionsMember 2019-04-01 2019-06-30 0001227636 stim:ProductCategoryMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember stim:OtherProductMember 2019-04-01 2019-06-30 0001227636 stim:ProductCategoryMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember 2019-04-01 2019-06-30 0001227636 country:US us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-06-30 0001227636 us-gaap:NonUsMember us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-06-30 0001227636 us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-06-30 0001227636 country:US us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-06-30 0001227636 us-gaap:NonUsMember us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-06-30 0001227636 us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-06-30 0001227636 stim:ProductCategoryMember country:US us-gaap:SalesRevenueNetMember stim:NeuroStarAdvancedTherapySystemMember 2020-01-01 2020-06-30 0001227636 stim:ProductCategoryMember country:US us-gaap:SalesRevenueNetMember stim:TreatmentSessionsMember 2020-01-01 2020-06-30 0001227636 stim:ProductCategoryMember country:US us-gaap:SalesRevenueNetMember stim:OtherProductMember 2020-01-01 2020-06-30 0001227636 stim:ProductCategoryMember country:US us-gaap:SalesRevenueNetMember 2020-01-01 2020-06-30 0001227636 stim:ProductCategoryMember country:US us-gaap:SalesRevenueNetMember stim:NeuroStarAdvancedTherapySystemMember 2019-01-01 2019-06-30 0001227636 stim:ProductCategoryMember country:US us-gaap:SalesRevenueNetMember stim:TreatmentSessionsMember 2019-01-01 2019-06-30 0001227636 stim:ProductCategoryMember country:US us-gaap:SalesRevenueNetMember stim:OtherProductMember 2019-01-01 2019-06-30 0001227636 stim:ProductCategoryMember country:US us-gaap:SalesRevenueNetMember 2019-01-01 2019-06-30 0001227636 stim:ProductCategoryMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember stim:NeuroStarAdvancedTherapySystemMember 2020-01-01 2020-06-30 0001227636 stim:ProductCategoryMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember stim:TreatmentSessionsMember 2020-01-01 2020-06-30 0001227636 stim:ProductCategoryMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember stim:OtherProductMember 2020-01-01 2020-06-30 0001227636 stim:ProductCategoryMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-06-30 0001227636 stim:ProductCategoryMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember stim:NeuroStarAdvancedTherapySystemMember 2019-01-01 2019-06-30 0001227636 stim:ProductCategoryMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember stim:TreatmentSessionsMember 2019-01-01 2019-06-30 0001227636 stim:ProductCategoryMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember stim:OtherProductMember 2019-01-01 2019-06-30 0001227636 stim:ProductCategoryMember us-gaap:NonUsMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-06-30 stim:Employee 0001227636 stim:ReductionInForceMember 2020-04-08 2020-04-08 0001227636 stim:ReductionInForceMember 2020-04-01 2020-06-30 0001227636 stim:TransitionSeparationAgreementMember 2020-04-10 2020-04-10 0001227636 us-gaap:OneTimeTerminationBenefitsMember stim:TransitionSeparationAgreementMember 2020-04-01 2020-06-30 0001227636 stim:TransitionSeparationAgreementMember 2020-06-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2020

OR

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

Commission File Number: 001-38546

NEURONETICS, INC.

(Exact name of registrant as specified in its charter)

Delaware | 33-1051425
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.)
3222 Phoenixville Pike, Malvern, PA | 19355
(Address of principal executive offices) | (Zip Code)

(610) 640-4202

(Registrant’s telephone number, including area code)

Not applicable.

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol (s) |  | Name on each exchange on which registered
Common Stock ($0.01 par value) |  | STIM |  | The Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ☐ |  | Accelerated filer | ☒
Non-accelerated filer | ☐ |  | Smaller reporting company | ☒
|  |  | Emerging growth company | ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

There were 18,862,148 shares of the registrant’s common stock outstanding as of July 31, 2020.

NEURONETICS, INC.

Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020

Table of Contents

|  |  |  | Page
PART I – FINANCIAL INFORMATION |
Item 1. |  | Financial Statements. |  | 3
|  | Balance Sheets as of June 30, 2020 and December 31, 2019 |  | 3
|  | Statements of Operations for the Three and Six Months ended June 30, 2020 and 2019 |  | 4
|  | Statement of Changes in Stockholders’ Equity for the Three and Six Months ended June 30, 2020 and 2019 |  | 5
|  | Statements of Cash Flows for the Six Months ended June 30, 2020 and 2019 |  | 6
|  | Notes to Interim Financial Statements |  | 7
Item 2. |  | Management’s Discussion and Analysis of Financial Condition and Results of Operations. |  | 20
Item 3. |  | Quantitative and Qualitative Disclosures About Market Risk. |  | 30
Item 4. |  | Controls and Procedures. |  | 30
PART II – OTHER INFORMATION |
Item 1. |  | Legal Proceedings. |  | 32
Item 1A. |  | Risk Factors. |  | 32
Item 2. |  | Unregistered Sales of Equity Securities and Use of Proceeds. |  | 32
Item 3. |  | Defaults Upon Senior Securities. |  | 32
Item 4. |  | Mine Safety Disclosures. |  | 32
Item 5. |  | Other Information. |  | 32
Item 6. |  | Exhibits. |  | 33
SIGNATURES |  | 34

2

PART I - FINANCIAL INFORMATION

Item 1. | Financial Statements.

NEURONETICS, INC.

Balance Sheets

(Unaudited; In thousands, except per share data)

|  | June 30, 2020 |  |  | December 31, 2019 |
Assets |  |  |  |  |  |  |  |
Current assets: |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 53,997 |  |  | $ | 75,708 |
Accounts receivable, net |  |  | 6,636 |  |  |  | 6,569 |
Inventory |  |  | 3,332 |  |  |  | 2,775 |
Current portion of net investments in sales-type leases |  |  | 1,305 |  |  |  | 880 |
Current portion of prepaid commission expense |  |  | 851 |  |  |  | 689 |
Prepaid expenses and other current assets |  |  | 1,091 |  |  |  | 1,830 |
Total current assets |  |  | 67,212 |  |  |  | 88,451 |
Property and equipment, net |  |  | 828 |  |  |  | 1,107 |
Operating lease right-of-use assets |  |  | 3,610 |  |  |  | 3,796 |
Net investments in sales-type leases |  |  | 2,082 |  |  |  | 1,730 |
Prepaid commission expense |  |  | 4,340 |  |  |  | 3,779 |
Other assets |  |  | 1,922 |  |  |  | 1,305 |
Total Assets |  | $ | 79,994 |  |  | $ | 100,168 |
Liabilities and Stockholders’ Equity |  |  |  |  |  |  |  |
Current liabilities: |  |  |  |  |  |  |  |
Accounts payable |  | $ | 2,324 |  |  | $ | 4,625 |
Accrued expenses |  |  | 5,661 |  |  |  | 9,031 |
Deferred revenue |  |  | 2,413 |  |  |  | 2,228 |
Current portion of operating lease liabilities |  |  | 577 |  |  |  | 559 |
Current portion of long-term debt, net |  |  | 34,373 |  |  |  | 11,250 |
Total current liabilities |  |  | 45,348 |  |  |  | 27,693 |
Long-term debt, net |  |  | - |  |  |  | 19,898 |
Deferred revenue |  |  | 1,935 |  |  |  | 2,106 |
Operating lease liabilities |  |  | 3,271 |  |  |  | 2,619 |
Total Liabilities |  |  | 50,554 |  |  |  | 52,316 |
Commitments and contingencies (Note 16) |  |  |  |  |  |  |  |
Stockholders’ Equity: |  |  |  |  |  |  |  |
Preferred stock, $0.01 par value: 10,000 shares authorized; no shares issued or outstanding at June 30, 2020 and December 31, 2019 |  |  | - |  |  |  | - |
Common stock, $0.01 par value: 200,000 shares authorized; 18,809 and 18,645 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively |  |  | 188 |  |  |  | 186 |
Additional paid-in capital |  |  | 299,717 |  |  |  | 297,753 |
Accumulated deficit |  |  | (270,465 | ) |  |  | (250,087 | )
Total Stockholders' Equity |  |  | 29,440 |  |  |  | 47,852 |
Total Liabilities and Stockholders’ Equity |  | $ | 79,994 |  |  | $ | 100,168 |

The accompanying notes are an integral part of these unaudited interim financial statements.

3

NEURONETICS, INC.

Statements of Operations

(Unaudited; In thousands, except per share data)

|  | Three Months Ended |  |  | Six Months Ended |
|  | June 30, |  |  | June 30, |
|  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
Revenues |  | $ | 9,741 |  |  | $ | 16,572 |  |  | $ | 21,217 |  |  | $ | 29,300 |
Cost of revenues |  |  | 2,323 |  |  |  | 4,171 |  |  |  | 5,134 |  |  |  | 6,978 |
Gross Profit |  |  | 7,418 |  |  |  | 12,401 |  |  |  | 16,083 |  |  |  | 22,322 |
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales and marketing |  |  | 8,151 |  |  |  | 11,523 |  |  |  | 18,874 |  |  |  | 21,115 |
General and administrative |  |  | 4,010 |  |  |  | 4,261 |  |  |  | 9,298 |  |  |  | 8,860 |
Research and development |  |  | 2,116 |  |  |  | 3,224 |  |  |  | 5,137 |  |  |  | 6,010 |
Total operating expenses |  |  | 14,277 |  |  |  | 19,008 |  |  |  | 33,309 |  |  |  | 35,985 |
Loss from Operations |  |  | (6,859 | ) |  |  | (6,607 | ) |  |  | (17,226 | ) |  |  | (13,663 | )
Other (income) expense: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest expense |  |  | 986 |  |  |  | 931 |  |  |  | 2,509 |  |  |  | 1,850 |
Loss on extinguishment of debt |  |  | - |  |  |  | - |  |  |  | 924 |  |  |  | - |
Other (income) expense, net |  |  | (80 | ) |  |  | (444 | ) |  |  | (281 | ) |  |  | (890 | )
Net Loss |  | $ | (7,765 | ) |  | $ | (7,094 | ) |  | $ | (20,378 | ) |  | $ | (14,623 | )
Net loss per share of common stock outstanding, basic and diluted |  | $ | (0.41 | ) |  | $ | (0.39 | ) |  | $ | (1.09 | ) |  |  | (0.80 | )
Weighted-average common shares outstanding, basic and diluted |  |  | 18,747 |  |  |  | 18,351 |  |  |  | 18,714 |  |  |  | 18,189 |

The accompanying notes are an integral part of these unaudited interim financial statements.

4

NEURONETICS, INC.

Statement of Changes in Stockholders’ Equity

(Unaudited; In thousands)

|  | Common Stock |  |  | Additional Paid-in |  |  | Accumulated |  |  | Total Stockholders’ |
|  | Shares |  |  | Amount |  |  | Capital |  |  | Deficit |  |  | Equity |
Balance at December 31, 2018 |  |  | 17,744 |  |  | $ | 177 |  |  | $ | 291,908 |  |  | $ | (221,043 | ) |  | $ | 71,042 |
Share-based awards and options exercises |  |  | 483 |  |  |  | 5 |  |  |  | 1,402 |  |  |  | - |  |  |  | 1,407 |
Share-based compensation expense |  |  | - |  |  |  | - |  |  |  | 501 |  |  |  | - |  |  |  | 501 |
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (7,529 | ) |  |  | (7,529 | )
Balance at March 31, 2019 |  |  | 18,227 |  |  | $ | 182 |  |  | $ | 293,811 |  |  | $ | (228,572 | ) |  | $ | 65,421 |
Share-based awards and options exercises |  |  | 218 |  |  |  | 2 |  |  |  | 468 |  |  |  | - |  |  |  | 470 |
Share-based compensation expense |  |  | - |  |  |  | - |  |  |  | 1,022 |  |  |  | - |  |  |  | 1,022 |
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (7,094 | ) |  |  | (7,094 | )
Balance at June 30, 2019 |  |  | 18,445 |  |  | $ | 184 |  |  | $ | 295,301 |  |  | $ | (235,666 | ) |  | $ | 59,819 |
Balance at December 31, 2019 |  |  | 18,645 |  |  | $ | 186 |  |  | $ | 297,753 |  |  | $ | (250,087 | ) |  | $ | 47,852 |
Share-based awards and options exercises |  |  | 81 |  |  |  | 1 |  |  |  | 75 |  |  |  | - |  |  |  | 76 |
Share-based compensation expense |  |  | - |  |  |  | - |  |  |  | 1,196 |  |  |  | - |  |  |  | 1,196 |
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (12,613 | ) |  |  | (12,613 | )
Balance at March 31, 2020 |  |  | 18,726 |  |  | $ | 187 |  |  | $ | 299,024 |  |  | $ | (262,700 | ) |  | $ | 36,511 |
Share-based awards and options exercises |  |  | 83 |  |  |  | 1 |  |  |  | 47 |  |  |  | - |  |  |  | 48 |
Share-based compensation expense |  |  | - |  |  |  | - |  |  |  | 646 |  |  |  | - |  |  |  | 646 |
Net loss |  |  | - |  |  |  | - |  |  |  | - |  |  |  | (7,765 | ) |  |  | (7,765 | )
Balance at June 30, 2020 |  |  | 18,809 |  |  | $ | 188 |  |  | $ | 299,717 |  |  | $ | (270,465 | ) |  | $ | 29,440 |

The accompanying notes are an integral part of these unaudited interim financial statements.

5

NEURONETICS, INC.

Statements of Cash Flows

(Unaudited; In thousands)

|  | Six Months Ended June 30, |
|  | 2020 |  |  | 2019 |
Cash Flows from Operating Activities: |  |  |  |  |  |  |  |
Net loss |  | $ | (20,378 | ) |  | $ | (14,623 | )
Adjustments to reconcile net loss to net cash used in operating activities: |  |  |  |  |  |  |  |
Depreciation and amortization |  |  | 534 |  |  |  | 457 |
Share-based compensation |  |  | 1,842 |  |  |  | 1,523 |
Non-cash interest expense |  |  | 944 |  |  |  | 362 |
Cost of rental units purchased by customers |  |  | 122 |  |  |  | 77 |
Loss on extinguishment of debt |  |  | 622 |  |  |  | - |
Changes in certain assets and liabilities: |  |  |  |  |  |  |  |
Accounts receivable, net |  |  | (66 | ) |  |  | (1,216 | )
Inventory |  |  | (557 | ) |  |  | (82 | )
Net investments in sales-type leases |  |  | (777 | ) |  |  | (640 | )
Leasehold reimbursement |  |  | 836 |  |  |  | - |
Prepaid commission expense |  |  | (723 | ) |  |  | (1,579 | )
Prepaid expenses and other assets |  |  | 356 |  |  |  | 941 |
Accounts payable |  |  | (2,408 | ) |  |  | (228 | )
Accrued expenses |  |  | (3,492 | ) |  |  | (1,044 | )
Deferred revenue |  |  | 14 |  |  |  | (366 | )
Net Cash Used in Operating Activities |  |  | (23,131 | ) |  |  | (16,418 | )
Cash Flows from Investing Activities: |  |  |  |  |  |  |  |
Purchases of property and equipment and capitalized software |  |  | (484 | ) |  |  | (398 | )
Net Cash Used in Investing Activities |  |  | (484 | ) |  |  | (398 | )
Cash Flows from Financing Activities: |  |  |  |  |  |  |  |
Proceeds from issuance of long-term debt |  |  | 41,360 |  |  |  | - |
Repayment of long-term debt |  |  | (38,860 | ) |  |  | - |
Payments of debt issuance costs |  |  | (721 | ) |  |  | - |
Proceeds from exercises of stock options |  |  | 124 |  |  |  | 1,877 |
Net Cash Provided by Financing Activities |  |  | 1,903 |  |  |  | 1,877 |
Net Decrease in Cash and Cash Equivalents |  |  | (21,711 | ) |  |  | (14,939 | )
Cash and Cash Equivalents, Beginning of Period |  |  | 75,708 |  |  |  | 104,583 |
Cash and Cash Equivalents, End of Period |  | $ | 53,997 |  |  | $ | 89,644 |
Supplemental disclosure of cash flow information: |  |  |  |  |  |  |  |
Cash paid for interest |  | $ | 2,227 |  |  | $ | 1,494 |
Transfer of inventory to property and equipment |  | $ | - |  |  | $ | 37 |
Supplemental disclosure of non-cash investing and financing activities: |  |  |  |  |  |  |  |
Purchases of property and equipment and capitalized software in accounts payable and accrued expenses |  | $ | - |  |  | $ | 13 |

The accompanying notes are an integral part of these unaudited interim financial statements.

6

NEURONETICS, INC.

Notes to Interim Financial Statements

(Unaudited)

1. | DESCRIPTION OF BUSINESS

Neuronetics, Inc., or the Company, is a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. The Company’s first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system was cleared in 2008 by the United States Food and Drug Administration, or the FDA, to treat adult patients with major depressive disorder, or MDD, who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar Advanced Therapy is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance. The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications.

COVID-19

The Company is monitoring the impact of the COVID-19 pandemic on all aspects of its business and geographies, including how it will impact the Company’s customers, supply chain, employees and other business partners. While the Company began to experience significant disruptions in March 2020 through the end of June 2020, from the COVID-19 pandemic, it is unable to predict the full impact that the COVID-19 pandemic may have on its financial condition, results of operations and cash flows due to numerous uncertainties. These uncertainties include the scope, severity and duration of the pandemic, the actions taken to contain the pandemic or mitigate its impact and the direct and indirect economic effects of the pandemic and containment measures, among others. The outbreak of COVID-19 in many countries, including the United States, has significantly adversely impacted global economic activity and has contributed to significant volatility and negative pressure in financial markets.

The Company applied for and received a $6.4 million loan in April 2020 under the Paycheck Protection Program (the “PPP”) established by the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) on March 27, 2020. Due to questions concerning the eligibility of public companies similarly situated to the Company, on May 7, 2020, the Company repaid the loan in full, including interest accrued to date.

Liquidity

As of June 30, 2020, the Company had cash and cash equivalents of $54.0 million and an accumulated deficit of $270.5 million. The Company incurred negative cash flows from operating activities of $30.5 million for the year ended December 31, 2019 and $23.1 million for the six months ended June 30, 2020. The Company has incurred operating losses since its inception, and management anticipates that its operating losses will continue in the near term as the Company continues to invest in sales, marketing and product development activities. The Company’s primary sources of capital to date have been proceeds from its IPO, private placements of its convertible preferred securities, borrowings under its credit facilities and revenues from sales of its products. As of June 30, 2020, the Company had $35.0 million of borrowings outstanding under its credit facility, which has a final maturity in February 2025. As discussed in Note 12, the outstanding balance under the credit facility is classified as a current liability as of June 30, 2020. Management believes that the Company’s cash and cash equivalents and anticipated revenues from sales of its products are sufficient to fund the Company’s operations (including the potential repayment of the credit facility if a waiver or amendment is not obtained) for at least 12 months from the issuance of these financial statements.

2. | BASIS OF PRESENTATION

The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles, or GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Updates, or ASUs, promulgated by the Financial Accounting Standards Board, or FASB.

Interim Financial Statements

The accompanying unaudited interim financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the United States Securities and Exchange Commission, or SEC, which permit reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the accompanying balance sheets and statements of operations and stockholders’ deficit and cash flows have been made. Although these interim financial statements do not include all of the information and footnotes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. Unaudited interim results of operations and cash flows for the three and six months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the full year. Unaudited interim financial statements and footnotes should be read in conjunction with the audited financial statements and footnotes included in the Company’s Form 10-K filed with the SEC on March 3, 2020, wherein a more complete discussion of significant accounting policies and certain other information can be found.

7

NEURONETICS, INC.

Notes to Interim Financial Statements

(Unaudited)

Use of Estimates

The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company’s business and evolving market conditions and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results.

3. | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company’s complete summary of significant accounting policies can be found in “Note 3. Summary of Significant Accounting Policies” in the audited financial statements included in the Company’s Form 10-K filed with the SEC on March 3, 2020.

4. | RECENT ACCOUNTING PRONOUNCEMENTS

New Accounting Standards Recently Adopted by the Company

In August 2018, the FASB issued ASU 2018-15, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract (“ASU 2018-15”), which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license).

ASU 2018-15 is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. The amendments in ASU 2018-15 should be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The Company adopted this standard on a prospective basis, effective January 1, 2020.

New Accounting Standards Not Yet Adopted by the Company

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“Topic 326”). This ASU provides guidance for recognizing credit losses on financial instruments based on an estimate of current expected credit losses model. The FASB subsequently issued ASU 2019-04, to clarify and address certain items related to the amendments in Topic 326.

ASU 2019-05, Financial Instruments - Credit Losses (Topic 326): Targeted Transition Relief, was issued to provide entities that have certain instruments within the scope of ASC 326 with an option to irrevocably elect the fair value option under ASC 825-10, Financial Instruments - Overall, applied on an instrument-by-instrument basis for eligible instruments.

These ASUs are effective for fiscal years beginning after December 15, 2022 for entities that are eligible to be defined by the SEC as a smaller reporting company. The Company is a smaller reporting company.

5. | FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS

The carrying values of cash equivalents, accounts receivable, prepaids and other current assets, and accounts payable on the Company’s balance sheets approximated their fair values as of June 30, 2020 and December 31, 2019 due to their short-term nature. The carrying values of the Company’s credit facility approximated its fair value as of June 30, 2020 and December 31, 2019 due to its variable interest rate.

8

NEURONETICS, INC.

Notes to Interim Financial Statements

(Unaudited)

Certain of the Company’s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

Level 1: | Inputs are quoted prices for identical instruments in active markets.
Level 2: | Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable.
Level 3: | Inputs are unobservable and reflect the Company’s own assumptions, based on the best information available, including the Company’s own data.

The following tables set forth the carrying amounts and fair values of the Company’s financial instruments as of June 30, 2020 and December 31, 2019 (in thousands):

|  | June 30, 2020 |
|  |  |  |  |  |  |  |  |  | Fair Value Measurement Based on |
|  | Carrying Amount |  |  | Fair Value |  |  | Quoted Prices In Active Markets (Level 1) |  |  | Significant other Observable Inputs (Level 2) |  |  | Significant Unobservable Inputs (Level 3) |
Assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Money market funds (cash equivalents) |  | $ | 51,362 |  |  | $ | 51,362 |  |  | $ | 51,362 |  |  | $ | - |  |  | $ | - |

|  | December 31, 2019 |
|  |  |  |  |  |  |  |  |  | Fair Value Measurement Based on |
|  | Carrying Amount |  |  | Fair Value |  |  | Quoted Prices In Active Markets (Level 1) |  |  | Significant other Observable Inputs (Level 2) |  |  | Significant Unobservable Inputs (Level 3) |
Assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Money market funds (cash equivalents) |  | $ | 67,650 |  |  | $ | 67,650 |  |  | $ | 67,650 |  |  | $ | - |  |  | $ | - |

6. | ACCOUNTS RECEIVABLE

The following table presents the composition of accounts receivable, net as of June 30, 2020 and December 31, 2019 (in thousands):

|  | June 30, 2020 |  |  | December 31, 2019 |
Gross accounts receivable - trade |  | $ | 7,990 |  |  | $ | 7,117 |
Less: Allowances for doubtful accounts |  |  | (1,354 | ) |  |  | (548 | )
Accounts receivable, net |  | $ | 6,636 |  |  | $ | 6,569 |

9

NEURONETICS, INC.

Notes to Interim Financial Statements

(Unaudited)

7. | PROPERTY AND EQUIPMENT AND CAPITALIZED SOFTWARE

The following table presents the composition of property and equipment, net as of June 30, 2020 and December 31, 2019 (in thousands):

|  | June 30, 2020 |  |  | December 31, 2019 |
Laboratory equipment |  | $ | 150 |  |  | $ | 150 |
Office equipment |  |  | 487 |  |  |  | 487 |
Computer equipment and software |  |  | 1,255 |  |  |  | 1,218 |
Manufacturing equipment |  |  | 273 |  |  |  | 273 |
Leasehold improvements |  |  | 423 |  |  |  | 423 |
Rental equipment |  |  | 519 |  |  |  | 763 |
Property and equipment, gross |  |  | 3,107 |  |  |  | 3,314 |
Less: Accumulated depreciation |  |  | (2,279 | ) |  |  | (2,207 | )
Property and equipment, net |  | $ | 828 |  |  | $ | 1,107 |

As of June 30, 2020 and December 31, 2019, the Company had capitalized software costs, net of $1.3 million and $1.2 million, respectively, which are included in “Other assets” on the balance sheet.

Depreciation and amortization expense was $0.2 million and $0.3 million for the three months ended June 30, 2020 and 2019, respectively and $0.5 million and $0.5 million for the six months ended June 30, 2020 and 2019, respectively .

8. | LEASES

Lessee:

The Company has operating leases for its corporate headquarters and office equipment, including copiers. The Company leases approximately 42,000 square foot facility in Malvern, Pennsylvania for its corporate headquarters, which includes office and warehouse space. The Company does not currently have any finance leases or executed leases that have not yet commenced.

Operating lease rent expense was $0.2 million and $0.3 million for the three and six months ended June 30, 2020 and 2019, respectively. As of June 30, 2020 the weighted-average remaining lease term of operating leases was 7.6 years and the weighted-average discount rate was 6.5%.

In the first quarter of 2020, the Company received a reimbursement of $0.8 million for leasehold expenses previously incurred in connection with the lease agreement for its Malvern facility. The reimbursement was recorded as an offset to the non-current lease liability that was established when the lease agreement was executed.

The following table presents the supplemental cash flow information as a lessee related to leases (in thousands):

|  | Six Months Ended |
|  | June 30, 2020 |  |  | June 30, 2019 |
Cash paid for amounts included in the measurement of lease liabilities: |  |  |  |  |  |  |  |
Operating cash flows from operating leases |  | $ | 394 |  |  | $ | 175 |
Right-of-use assets obtained in exchange for lease obligations: |  |  |  |  |  |  |  |
Operating leases |  | $ | - |  |  | $ | 4,164 |

10

NEURONETICS, INC.

Notes to Interim Financial Statements

(Unaudited)

The following table sets forth by year the required future payments of operating lease liabilities (in thousands):

|  | June 30, 2020 |
Remainder of 2020 |  | $ | 297 |
2021 |  |  | 616 |
2022 |  |  | 641 |
2023 |  |  | 637 |
2024 |  |  | 646 |
Thereafter |  |  | 2,147 |
Total lease payments |  |  | 4,984 |
Less imputed interest |  |  | (1,136 | )
Present value of operating lease liabilities |  | $ | 3,848 |

Lessor sales-type leases:

Certain customers have purchased NeuroStar Advanced Therapy Systems on a rent-to-own basis. The lease term is three years with a customer option to purchase the NeuroStar Advanced Therapy System at the end of the lease or automatic transfer of ownership of the NeuroStar Advanced Therapy System at the end of the lease.

The following table sets forth the profit recognized on sales-type leases (in thousands):

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
Profit recognized at commencement, net |  | $ | 474 |  |  | $ | 118 |  |  | $ | 726 |  |  | $ | 262 |
Interest income |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Total sales-type lease income |  | $ | 474 |  |  | $ | 118 |  |  | $ | 726 |  |  | $ | 262 |

The following table sets forth a maturity analysis of the undiscounted lease receivables related to sales-type leases (in thousands):

|  | June 30, 2020 |
Remainder of 2020 |  | $ | 653 |
2021 |  |  | 1,347 |
2022 |  |  | 1,143 |
2023 |  |  | 244 |
Total sales-type lease receivables |  | $ | 3,387 |

As of June 30, 2020, the carrying amount of the lease receivables is $3.4 million. The Company does not have any unguaranteed residual assets.

Lessor operating leases:

NeuroStar Advanced Therapy Systems sold on a rent-to-own basis prior to January 1, 2019 are accounted for as operating leases. For the three months ended June 30, 2020 and 2019, the Company recognized operating lease income of $0.1 million in each period. For the six months ended June 30, 2020 and June 30, 2019, the Company recognized operating lease income of $0.2 million and $0.3 million, respectively.

The following table sets forth a maturity analysis of its undiscounted lease receivables related to operating leases:

|  | June 30, 2020 |
Remainder of 2020 |  | $ | 280 |
2021 |  |  | 150 |
Total lease receivables |  | $ | 430 |

11

NEURONETICS, INC.

Notes to Interim Financial Statements

(Unaudited)

The Company maintained Rental Equipment, net of $0.3 million and $0.5 million, as of June 30, 2020 and December 31, 2019, respectively, which are included in “Property and equipment, net” on the balance sheet. Rental equipment depreciation expense was $0.02 million and $0.05 million for the three months ended June 30, 2020 and 2019, respectively and $0.05 million and $0.1 million for the six months ended June 30, 2020 and 2019 .

9. | PREPAID COMMISSION EXPENSE

The Company pays a commission on both System sales and Treatment Session sales. Since the commission paid for System sales is not commensurate with the commission paid for Treatment Sessions, the Company capitalizes commission expense associated with System sales commissions paid that is incremental to specifically anticipated future Treatment Session orders. In developing this estimate, the Company considered its historical Treatment Session sales and customer retention rates, as well as technology development life cycles and other industry factors. These costs are periodically reviewed for impairment.

NeuroStar Advanced Therapy System commissions are deferred and amortized on a straight-line basis over a seven year period equal to the average customer term, which the Company deems to be the expected period of benefit for these costs.

On the Company's balance sheets, the current portion of capitalized contract costs is represented by the current portion of prepaid commission expense, while the long-term portion is included in prepaid commission expense. Amortization expense was $0.2 million and $0.04 million for the three months ended June 30, 2020 and 2019, respectively, and $0.4 million and $0.1 million for the six months ended June 30, 2020 and 2019, respectively.

10. | ACCRUED EXPENSES

The following table presents the composition of accrued expenses as of June 30, 2020 and December 31, 2019 (in thousands):

|  | June 30, 2020 |  |  | December 31, 2019 |
Compensation and related benefits |  | $ | 3,288 |  |  | $ | 5,724 |
Consulting and professional fees |  |  | 557 |  |  |  | 373 |
Research and development expenses |  |  | 368 |  |  |  | 674 |
Sales and marketing expenses |  |  | 113 |  |  |  | 127 |
Warranty |  |  | 559 |  |  |  | 639 |
Sales and other taxes payable |  |  | 432 |  |  |  | 700 |
Interest payable |  |  | - |  |  |  | 234 |
Other |  |  | 344 |  |  |  | 560 |
Accrued expenses |  | $ | 5,661 |  |  | $ | 9,031 |

11. | DEFERRED REVENUE

Payment terms typically require payment upon shipment or installation of the System and additional payments as access codes for Treatment Sessions are delivered, which can span several years after the System is first delivered and installed. The timing of revenue recognition compared to billings and cash collections typically results in accounts receivable. However, sometimes customer advances and deposits might be required for certain customers and are recorded as deferred revenue. For multi-year agreements, the Company generally invoices customers annually at the beginning of each annual coverage period and recognizes revenue over the term of the coverage period.

As of June 30, 2020, the Company expects to recognize approximately the following percentages of deferred revenue by year:

Year: |  | Revenue Recognition |
Remainder of 2020 |  |  | 42 | %
2021 |  |  | 17 | %
2022 |  |  | 12 | %
2023 |  |  | 13 | %
2024 |  |  | 13 | %
Thereafter |  |  | 3 | %
Total |  |  | 100 | %

12

NEURONETICS, INC.

Notes to Interim Financial Statements

(Unaudited)

Revenue recognized for the three and six months ended June 30, 2020 that was included in the contract liability balance at the beginning of the year was $0.4 million and $1.3 million respectively, and primarily represented revenue earned from separately priced extended warranties, rent-to-own revenue, milestone revenue, and clinical training.

Customers

For the three and six months ended June 30, 2020 one customer accounted for more than 10% of the Company’s revenues. No customer accounted for more than 10% of the Company’s revenues for the same periods in 2019.

1 2. | DEBT

The following table presents the composition of debt as of June 30, 2020 and December 31, 2019 (in thousands):

|  | June 30, 2020 |  |  | December 31, 2019 |
Outstanding principal |  | $ | 35,000 |  |  | $ | 30,000 |
Accrued final payment fees |  |  | 1,925 |  |  |  | 1,838 |
Less debt discounts |  |  | (2,552 | ) |  |  | (690 | )
Total debt, net |  |  | 34,373 |  |  |  | 31,148 |
Less current portion |  |  | (34,373 | ) |  |  | (11,250 | )
Long-term debt, net |  | $ | - |  |  | $ | 19,898 |

For the three months ended June 30, 2020, the Company recognized interest expense of $1.0 million, of which $0.8 million was cash and $0.2 million was non-cash interest expense related to the amortization of deferred debt issuance costs and accrual of final payment fees. For the three months ended June 30, 2019, the Company recognized interest expense of $0.9 million, of which $0.7 million was cash paid for interest during the period and $0.2 million was non-cash interest expense related to the amortization of deferred debt issuance costs and accrual of final payment fees.

For the six months ended June 30, 2020, the Company recognized interest expense of $2.5 million, of which $2.2 million was cash and $0.3 million was non-cash interest expense related to the amortization of deferred debt issuance costs and accrual of final payment fees. For the six months ended June 30, 2019, the Company recognized interest expense of $1.9 million, of which $1.5 million was cash paid for interest during the period and $0.4 million was non-cash interest expense related to the amortization of deferred debt issuance costs and accrual of final payment fees.

Solar Credit Facility

On March 2, 2020, the “Company entered into a loan and security agreement with Solar Capital Ltd., or Solar, as collateral agent, and other lenders defined in the agreement, for a credit facility, or the Solar Facility, that replaced the Company’s previous $35.0 million credit facility with Oxford Finance LLC, or Oxford, and such facility, the Oxford Facility.

The Solar Facility permits the Company to borrow up to an aggregate amount of $50.0 million in two tranches of term loans, a “Term A Loan” and “Term B Loan.” On March 2, 2020, the Company borrowed an aggregate amount of $35.0 million, which was the aggregate amount available under the Term A Loan portion of the Solar Facility. The Term A Loan portion of the Solar Facility matures, and all amounts borrowed thereunder are due, on February 28, 2025. Under the Term B Loan portion of the Solar Facility, the Company is permitted to borrow, at its election, up to an aggregate amount of $15.0 million, (i) upon the Company achieving a specified amount of trailing twelve months net product revenue, and (ii) assuming there has been no event of default under the Solar Facility prior to such election. Once the net product revenue condition has been satisfied, the Company may only make an election to borrow under the Term B Loan portion of the Solar Facility until the earlier of (a) December 15, 2021, (b) 30 days following achievement of the net product revenue condition or (c) the occurrence of an event of default.

Each of the Term A Loan and Term B Loan accrue interest from the date of borrowing through the date of repayment at a floating per annum rate of interest, which resets monthly and is equal to 7.65% plus the greater of (a) 1.66% or (b) the rate per annum rate published by the Intercontinental Exchange Benchmark Administration Ltd. The Term A Loan and the Term B Loan both include an interest-only period through March 1, 2022, after which time the Company will be required to make monthly payments of principal and interest. Monthly principal payments are to be paid in equal amounts on a pro rata basis to lenders. At the Company’s election, the interest only period may be extended through February 2023 if the Company satisfies a minimum net product revenue covenant through March 1, 2022 and no event of default shall have occurred.

13

NEURONETICS, INC.

Notes to Interim Financial Statements

(Unaudited)

In addition to the principal and interest payments due under the Solar Facility, the Company is required to pay a final payment fee to Solar due upon the earlier of prepayment, acceleration or the maturity date of the Term A Loan or Term B Loan portion of the Solar Facility equal to 5.50% of the principal amount of the term loans actually funded. The Company is accruing the final payment fees using the effective interest rate, with a charge to non-cash interest expense, over the term of borrowing. If the Company prepays either the of the Term A Loan or Term B Loan prior to their respective scheduled maturities, the Company will also be required to pay prepayment fees to Solar equal to 3% of the principal amount of such term loan then-prepaid if prepaid on or before the first anniversary of funding, 2% of the principal amount of such term loan then-prepaid if prepaid after the first anniversary and on or before the second anniversary of funding, or 1% of the principal amount of such term loan then-prepaid if prepaid after the second anniversary of funding of the principal amounts borrowed.

The Company is also required to pay Solar an exit fee upon the occurrence, prior to March 2, 2030, of (a) any liquidation, dissolution or winding up of the Company, (b) transaction that results in a person obtaining control over the Company, (c) the Company achieving $100 million in trailing twelve month net product revenue or (d) the Company achieving $125 million in trailing twelve month net product revenue. The exit fee for liquidation, dissolution, winding up or change of control of the Company is equal to 4.50% of the principal amount of the term loans actually funded. The exit fee for achieving either $100 million or $125 million in trailing twelve-month net product revenue is equal to 2.25% of the principal amount of the term loans actually funded or, if both net product revenue milestones are achieved, 4.50% of the principal amount of the term loans actually funded. The exit fee is capped at 4.50% of the principal amount of the term loans actually funded.

The Company’s obligations under the Solar Facility are secured by a first priority security interest in substantially all of its assets, including its intellectual property. The loan and security agreement requires the Company to comply with certain financial covenants as well as customary affirmative and negative covenants.

The Solar Facility contains events of default, including, without limitation, events of default upon: (i) failure to make payment pursuant to the terms of the agreement; (ii) violation of covenants; (iii) material adverse changes to the Company’s business; (iv) attachment or levy on the Company’s assets or judicial restraint on its business; (v) insolvency; (vi) material cross-defaults; (vii) significant judgments, orders or decrees for payments by the Company not covered by insurance; (viii) incorrectness of representations and warranties; (ix) incurrence of subordinated debt; (x) a termination or breach of a guaranty; (xi) revocation of governmental approvals necessary for the Company to conduct its business; and (xii) failure by the Company to maintain a valid and perfected lien on the collateral securing the borrowing.

As of June 30, 2020, the Company is in compliance with all covenants in the Solar Facility.

The Solar Facility includes a financial covenant requiring the attainment of a minimum trailing net revenue amount beginning on December 31, 2020. Based upon the Company’s projected revenues for the rest of 2020, the Company believes that it is probable that this minimum revenue covenant will not be achieved. The Company is in discussions with the lenders for a potential covenant waiver or amendment, however, no formal agreement has been executed. The Solar Facility also includes subjective acceleration clauses which permit the lenders to accelerate the maturity date under certain circumstances, including, but not limited to, material adverse effects on a Company’s financial status or otherwise. In accordance with FASB ASC 470 because the Solar Facility contains subjective acceleration clauses and the assessment that it is probable that the revenue covenant will not be met as of December 31, 2020, the outstanding principal under the Solar Facility is classified as a current liability in the accompanying balance sheet as of June 30, 2020.

Oxford Credit Facility

Prior to March 2020, the Company had a $35.0 million credit facility in place with Oxford, which it entered into in March 2017 and that allowed it to borrow up to $35.0 million in three tranches of term loans: a Term A Loan in the amount of $25 million, which was drawn immediately upon closing in March 2017, a Term B Loan in the amount of $5.0 million, which was drawn down in December 2017, and a Term C Loan in the amount of $5.0 million which was never drawn down. Each term loan accrued interest from the date of borrowing through the date of repayment at a floating per annum rate of interest, which reset monthly and was equal to the greater of (a) 8.15% or (b) the 30 day U.S. LIBOR on the last business day of the month plus 7.38%. This facility featured an interest-only period on all tranches through March 2019.

14

NEURONETICS, INC.

Notes to Interim Financial Statements

(Unaudited)

In addition to principal and interest payments due under the $35.0 million Oxford credit facility, the Company was required to make final payment fees to Oxford upon the earlier of prepayment or maturity and equal to 8.5% and 7.5% of the principal amounts of the Term A and Term B Loans, respectively. The Company accrued final payment fees using the effective interest rate, with a charge to non-cash interest expense, over the term of borrowing and until its entry into the Solar credit facility in March 2020, at which time the Company paid Oxford $2.5 million in satisfaction of all final payment fee liabilities due under the Oxford credit facility.

The Company evaluated whether the Solar Facility entered into in March 2020 represented a debt modification or extinguishment in accordance with ASC 470-50, Debt—Modifications and Extinguishments and determined that the existing debt was extinguished as a result of the full repayment of the existing facility and concurrent issuance of a new credit facility with a new lender. The unamortized balance of the Company’s combined debt discount and deferred issuance costs of $0.6 million related to the Oxford facility were accounted for as a loss on extinguishment of debt.

1 3. | COMMON STOCK

Common Stock

The following table summarizes the total number of shares of the Company’s common stock issued and reserved for issuance as of June 30, 2020 and December 31, 2019 (in thousands):

|  | June 30, 2020 |  |  | December 31, 2019 |
Shares of common stock issued |  |  | 18,809 |  |  |  | 18,645 |
Shares of common stock reserved for issuance for: |  |  |  |  |  |  |  |
Common stock warrants outstanding |  |  | 105 |  |  |  | 105 |
Stock options outstanding |  |  | 1,865 |  |  |  | 2,415 |
Restricted stock units outstanding |  |  | 1,289 |  |  |  | 245 |
Shares available for grant under stock incentive plan |  |  | 1,295 |  |  |  | 1,215 |
Shares available for sale under employee stock purchase plan |  |  | 608 |  |  |  | 421 |
Total shares of common stock issued and reserved for issuance |  |  | 23,971 |  |  |  | 23,046 |

Common Stock Warrants

The following table summarizes the Company’s outstanding common stock warrants as of June 30, 2020 and December 31, 2019:

Warrants Outstanding (in thousands) |  |  | Exercise Price |  |  | Expiration Date
| 14 |  |  | $ | 19.55 |  |  | Dec-2022
| 30 |  |  | $ | 9.73 |  |  | Feb-2021
| 20 |  |  | $ | 9.73 |  |  | Aug-2023
| 20 |  |  | $ | 9.73 |  |  | Mar-2024
| 21 |  |  | $ | 9.73 |  |  | Dec-2024
| 105 |  |  |  |  |  |  |

1 4. | LOSS PER SHARE

The Company’s basic loss per common share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. The Company’s restricted stock awards (non-vested shares) are issued and outstanding at the time of grant but are excluded from the Company’s computation of weighted-average shares outstanding in the determination of basic loss per share until vesting occurs.

A net loss cannot be diluted, so when the Company is in a net loss position, basic and diluted loss per common share are the same. If in the future the Company achieves profitability, the denominator of a diluted earnings per common share calculation will include both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and non-vested restricted stock awards and units using the treasury stock method, along with the effect, if any, from the potential conversion of outstanding securities, such as convertible preferred stock.

15

NEURONETICS, INC.

Notes to Interim Financial Statements

(Unaudited)

The following potentially dilutive securities outstanding as of June 30, 2020 and 2019 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):

|  | June 30, |
|  | 2020 |  |  | 2019 |
Stock options |  |  | 1,865 |  |  |  | 2,507 |
Non-vested restricted stock awards |  |  | - |  |  |  | - |
Non-vested restricted stock units |  |  | 1,289 |  |  |  | 184 |
Common stock warrants |  |  | 105 |  |  |  | 105 |

1 5. | SHARE-BASED COMPENSATION

The amount of share-based compensation expense recognized by the Company by location in its statements of operations for the three and six months ended June 30, 2020 and 2019 is as follows (in thousands):

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
Cost of revenues |  | $ | 15 |  |  | $ | 19 |  |  | $ | 31 |  |  | $ | 29 |
Sales and marketing |  |  | 236 |  |  |  | 404 |  |  |  | 666 |  |  |  | 608 |
General and administrative |  |  | 261 |  |  |  | 479 |  |  |  | 868 |  |  |  | 697 |
Research and development |  |  | 134 |  |  |  | 120 |  |  |  | 277 |  |  |  | 189 |
Total |  | $ | 646 |  |  | $ | 1,022 |  |  | $ | 1,842 |  |  | $ | 1,523 |

2018 Equity Incentive Plan

In June 2018, the Company adopted the 2018 Equity Incentive Plan, or 2018 Plan, which authorized the issuance of up to 1.4 million shares, subject to an annual 4% increase based on the number of shares of common stock outstanding, in the form of restricted stock, stock appreciation rights and stock options to the Company’s directors, employees and consultants. The amount and terms of grants are determined by the Company’s board of directors. All stock options granted to date have had exercise prices equal to the fair value, as determined by the closing price as reported by the Nasdaq Global Market, of the underlying common stock on the date of grant. The contractual term of stock options is up to 10 years, and stock options are exercisable in cash or as otherwise determined by the board of directors. Generally, stock options vest 25% upon the first anniversary of the date of grant and the remainder ratably monthly thereafter for 36 months. Restricted stock awards and restricted stock units vest ratably in three equal installments on the first, second and third anniversaries of the grant date. As of June 30, 2020, there were 1.3 million shares available for future issuance under the 2018 Plan.

Stock Options

The following table summarizes the Company’s stock option activity for the six months ended June 30, 2020:

|  | Number of Shares under Option (in thousands) |  |  | Weighted- average Exercise Price per Option |  |  | Weighted- average Remaining Contractual Life (in years) |  |  | Aggregate Intrinsic Value (in thousands) |
Outstanding at December 31, 2019 |  |  | 2,415 |  |  | $ | 7.11 |  |  |  |  |  |  |  |  |
Granted |  |  | 28 |  |  | $ | 2.94 |  |  |  |  |  |  |  |  |
Exercised |  |  | (98 | ) |  | $ | 1.28 |  |  |  |  |  |  |  |  |
Forfeited |  |  | (480 | ) |  | $ | 11.16 |  |  |  |  |  |  |  |  |
Outstanding at June 30, 2020 |  |  | 1,865 |  |  | $ | 6.31 |  |  |  | 5.2 |  |  | $ | 527 |
Exercisable at June 30, 2020 |  |  | 1,312 |  |  | $ | 4.63 |  |  |  | 3.8 |  |  | $ | 527 |
Vested and expected to vest at June 30, 2020 |  |  | 1,865 |  |  | $ | 6.31 |  |  |  | 5.2 |  |  | $ | 527 |

16

NEURONETICS, INC.

Notes to Interim Financial Statements

(Unaudited)

The Company recognized share-based compensation expense related to stock options of $0.3 million and $0.7 million for the three months ended June 30, 2020 and 2019, respectively and $0.8 million and $1.0 million for the six months ended June 30, 2020 and June 30, 2019. As of June 30, 2020, there was $2.8 million of total unrecognized compensation cost related to non-vested stock options which the Company expects to recognize over a weighted-average period of 2.6 years. The weighted-average grant-date fair value of stock options granted during the six months ended June 30, 2020 was estimated at $1.52 per option. The total intrinsic value of stock options exercised during the six months ended June 30, 2020 was $0.2 million.

For the six months ended June 30, 2020, the grant-date fair value of stock options was estimated at the time of grant using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:

Estimated fair value of common stock |  | $ | 2.94 |
Exercise price |  | $ | 2.94 |
Expected term (in years) |  |  | 6.1 |
Risk-free interest rate |  |  | 1 | %
Expected volatility |  |  | 55 | %
Dividend yield |  |  | 0 | %

Restricted Stock Awards and Restricted Stock Units

The following table summarizes the Company’s restricted stock award and restricted stock unit activity for the six months ended June 30, 2020:

|  | Non-vested Restricted Stock Units (in thousands) |  |  | Weighted- average Grant-date Fair Value |
Non-vested at December 31, 2019 |  |  | 245 |  |  | $ | 15.23 |
Granted |  |  | 1,504 |  |  | $ | 3.40 |
Vested |  |  | (66 | ) |  | $ | 15.26 |
Forfeited |  |  | (394 | ) |  | $ | 5.34 |
Non-vested at June 30, 2020 |  |  | 1,289 |  |  | $ | 4.45 |

The Company recognized $0.4 million and $0.3 million in share-based compensation expense related to restricted stock awards and restricted stock units for the three months ended June 30, 2020 and 2019, respectively and $1.0 million and $0.5 million for the six months ended June 30, 2020 and 2019. As of June 30, 2020, there was $4.8 million of unrecognized compensation cost related to non-vested restricted stock awards and restricted stock units, which the Company expects to recognize over a weighted-average period of 2.3 years. The total fair value at the vesting date of restricted stock awards and restricted stock units vested during the six months ended June 30, 2020 was $0.2 million.

16.COMMITMENTS AND CONTINGENCIES

Executive Employment Agreements

The Company has entered into an employment agreement and offer letters with certain key executives, providing for compensation and severance in certain circumstances, as defined in the agreements. In connection with the separation agreement with our former chief executive officer, the Company recorded $0.0 million and $1.1 million in general administrative expense during thethree and six months ended June 30, 2020

Legal Matters

The Company is subject from time to time to various claims and legal actions arising during the ordinary course of its business. Management believes that there are currently no claims or legal actions that would reasonably be expected to have a material adverse effect on the Company’s results of operations, financial condition, or cash flows.

17

NEURONETICS, INC.

Notes to Interim Financial Statements

(Unaudited)

1 7. | GEOGRAPHICAL SEGMENT INFORMATION

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company currently operates in one business segment as it is managed and operated as one business. A single management team that reports to the chief operating decision maker comprehensively manages the entire business. The Company does not operate any material separate lines of business or separate business entities with respect to its products or product development.

The following geographic data includes revenue generated from the Company’s third-party distributors. The Company’s revenue was generated in the following geographic regions and by product line for the periods indicated (in thousands):

|  | Revenues by Geography |
|  | Three Months Ended June 30, |
|  | 2020 |  |  | 2019 |
|  | Amount |  |  | % of Revenues |  |  | Amount |  |  | % of Revenues |
United States |  | $ | 9,267 |  |  |  | 95 | % |  | $ | 15,890 |  |  |  | 96 | %
International |  |  | 474 |  |  |  | 5 | % |  |  | 682 |  |  |  | 4 | %
Total revenues |  | $ | 9,741 |  |  |  | 100 | % |  | $ | 16,572 |  |  |  | 100 | %

|  | U.S. Revenues by Product Category Three Months Ended June 30, |
|  | 2020 |  |  | 2019 |
|  | Amount |  |  | % of Revenues |  |  | Amount |  |  | % of Revenues |
|  | (in thousands, except percentages) |
NeuroStar Advanced Therapy System |  | $ | 2,338 |  |  |  | 25 | % |  | $ | 4,628 |  |  |  | 29 | %
Treatment sessions |  |  | 6,547 |  |  |  | 71 | % |  |  | 10,847 |  |  |  | 68 | %
Other |  |  | 382 |  |  |  | 4 | % |  |  | 415 |  |  |  | 3 | %
Total U.S. revenues |  | $ | 9,267 |  |  |  | 100 | % |  | $ | 15,890 |  |  |  | 100 | %

|  | International Revenues by Product Category Three Months Ended June 30, |
|  | 2020 |  |  | 2019 |
|  | Amount |  |  | % of Revenues |  |  | Amount |  |  | % of Revenues |
|  | (in thousands, except percentages) |
NeuroStar Advanced Therapy System |  | $ | 310 |  |  |  | 66 | % |  | $ | 465 |  |  |  | 68 | %
Treatment sessions |  |  | 115 |  |  |  | 24 | % |  |  | 114 |  |  |  | 17 | %
Other |  |  | 49 |  |  |  | 10 | % |  |  | 103 |  |  |  | 15 | %
Total International revenues |  | $ | 474 |  |  |  | 100 | % |  | $ | 682 |  |  |  | 100 | %

|  | Revenues by Geography |
|  | Six Months Ended June 30, |
|  | 2020 |  |  | 2019 |
|  | Amount |  |  | % of Revenues |  |  | Amount |  |  | % of Revenues |
United States |  | $ | 20,444 |  |  |  | 96 | % |  | $ | 28,436 |  |  |  | 97 | %
International |  |  | 773 |  |  |  | 4 | % |  |  | 864 |  |  |  | 3 | %
Total revenues |  | $ | 21,217 |  |  |  | 100 | % |  | $ | 29,300 |  |  |  | 100 | %

18

NEURONETICS, INC.

Notes to Interim Financial Statements

(Unaudited)

|  | U.S. Revenues by Product Category Six Months Ended June 30, |
|  | 2020 |  |  | 2019 |
|  | Amount |  |  | % of Revenues |  |  | Amount |  |  | % of Revenues |
|  | (in thousands, except percentages) |
NeuroStar Advanced Therapy System |  | $ | 4,932 |  |  |  | 24 | % |  | $ | 7,978 |  |  |  | 28 | %
Treatment sessions |  |  | 14,740 |  |  |  | 72 | % |  |  | 19,625 |  |  |  | 69 | %
Other |  |  | 772 |  |  |  | 4 | % |  |  | 833 |  |  |  | 3 | %
Total U.S. revenues |  | $ | 20,444 |  |  |  | 100 | % |  | $ | 28,436 |  |  |  | 100 | %

|  | International Revenues by Product Category Six Months Ended June 30, |
|  | 2020 |  |  | 2019 |
|  | Amount |  |  | % of Revenues |  |  | Amount |  |  | % of Revenues |
|  | (in thousands, except percentages) |
NeuroStar Advanced Therapy System |  | $ | 410 |  |  |  | 53 | % |  | $ | 537 |  |  |  | 62 | %
Treatment sessions |  |  | 192 |  |  |  | 25 | % |  |  | 133 |  |  |  | 15 | %
Other |  |  | 171 |  |  |  | 22 | % |  |  | 194 |  |  |  | 23 | %
Total International revenues |  | $ | 773 |  |  |  | 100 | % |  | $ | 864 |  |  |  | 100 | %

18. SEVERANCE

On April 8, 2020, the Company took action to reduce expenses through a reduction in force (“RIF”). As part of this action the Company terminated 95 employees who received separation benefits upon their termination. During the second quarter of 2020, the Company recorded a separation-related charge for the RIF equal to the fair value of the terminated employees benefits as of the communication date in the amount of $2.1 million. This amount was paid out during the quarter with the final payoff occurring on June 15, 2020.

On April 10, 2020 the company entered into a transition agreement outlining the separation with its former chief executive officer. In connection with this agreement the company recorded $1.1 million of charges in salary, payroll tax and bonus expenses. During the second quarter, $0.3 million of termination benefits were paid associated with the termination of the employee and charged against this liability. There was no other changes to the liability. As of June 30, 2020, $0.8 million remain in accrued liabilities for the unpaid portion of the separation benefits.

19

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations, as well as other sections in this Quarterly Report on Form 10-Q, should be read in conjunction with our unaudited interim financial statements and related notes thereto included elsewhere herein. In addition to historical financial information, some of the information contained in the following discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts, including statements regarding our future results of operations and financial position, business strategy, current and prospective products, product approvals, research and development costs, current and prospective collaborations, timing and likelihood of success, plans and objectives of management for future operations and future results of current and anticipated products, are forward-looking statements. These statements involve known and unknown risks, uncertainties, assumptions and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, without limitation, risks and uncertainties related to: the impact of the novel coronavirus, or COVID-19, pandemic on general political and economic conditions, including as a result of efforts by governmental authorities to mitigate the COVID-19 pandemic, such as travel bans, shelter in place orders and third-party business closures and the related impact on resource allocations, manufacturing and supply chains and patient access to commercial products; our ability to execute our business continuity as well as our operational and budget plans in light of the COVID-19 pandemic; our ability to achieve or sustain profitable operations due to our history of losses; our reliance on the sale and usage of our NeuroStar Advanced Therapy System to generate revenues; the scale and efficacy of our salesforce; availability of coverage and reimbursement from third-party payors for treatments using our products; physician and patient demand for treatments using our products; developments in respect of competing technologies and therapies for the indications that our products treat; product defects; our ability to obtain and maintain intellectual property protection for our technology; developments in clinical trials or regulatory review of NeuroStar Advanced Therapy System for additional indications; and developments in regulation in the United States and other applicable jurisdictions. For a discussion of these and other related risks, please refer to our recent SEC filings which are available on the SEC’s website at www.sec.gov. These forward-looking statements are based on our expectations and assumptions as of the date of this Quarterly Report on Form 10-Q. Except as required by law, we undertake no duty or obligation to update any forward-looking statements contained in this Quarterly Report on Form 10-Q as a result of new information, future events or changes in our expectations.

20

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K filed with the SEC, on March 3, 20 20. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for us to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Overview

We are a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Our first commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, to treat adult patients with major depressive disorder, or MDD, that have failed to achieve satisfactory improvement from prior antidepressant medication in the current MDD episode. NeuroStar Advanced Therapy is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance. NeuroStar Advanced Therapy is safe, clinically effective, reproducible and precise and we believe is supported by the largest clinical data set of any competing TMS system. We are a market leader in TMS therapy based on our U.S. installed base of 1,122 active NeuroStar Advanced Therapy Systems in approximately 889 psychiatrist offices as of June 30, 2020 and the estimated 89,368 patients treated with approximately 3.2 million of our treatment sessions through such date. We generated revenues of $9.7 million and $21.2 million for the three and six months ended June 30, 2020.

We designed the NeuroStar Advanced Therapy System as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of other treatment options. We generate revenues from initial capital sales of our systems, recurring Treatment Sessions and service and repair and extended warranty contracts. We derive the majority of our revenues from recurring Treatment Sessions. For the three months ended June 30, 2020, revenues from sales of our Treatment Sessions and NeuroStar Advanced Therapy Systems represented 71% and 25% of our U.S. revenues, respectively. For the six months ended June 30, 2020, revenues from sales of our Treatment Sessions and NeuroStar Advanced Therapy Systems represented 72% and 24% of our U.S. revenues, respectively.

We currently sell our NeuroStar Advanced Therapy System and recurring Treatment Sessions in the United States with the collaborative support of our 114 employees as of June 30, 2020. Our sales force primarily targets 20,600 psychiatrists at 5,700 psychiatric practices that we estimate, based on data from Symphony Health and our own internal estimates, treat approximately 42% of the total MDD patients in the United States who meet our labeled indication and are insured. Some of our customers have and may purchase more than one NeuroStar Advanced Therapy System. Based on our commercial data, we believe psychiatrists can recoup their initial capital investment in our system by providing a standard course of treatment to approximately 12 patients. We believe psychiatrists can generate approximately $7,500 to $10,000 of revenue per patient for a standard course of treatment, which may provide meaningful incremental income to their practices. We have a diverse customer base of psychiatrists in group psychiatric practices in the United States. For the three and six months ended June 30, 2020, one customer accounted for more than 10% of our revenues.

We market our products in a few select markets outside the United States through independent distributors. International revenues represented 4% and 3% of our total revenues for the six months ended June 30, 2020 and June 30, 2019, respectively. In October 2017, we entered into an exclusive distribution agreement with Teijin Pharma Limited, or Teijin, for the distribution of our NeuroStar Advanced Therapy Systems and Treatment Sessions to customers who will treat patients with MDD in Japan. We received regulatory approval for our system in Japan in September 2017, and we received the initial reimbursement of JPY 12,000 per Treatment Session, which went into effect on June 1, 2019. We expect our international revenues to increase over time as a percentage of our total revenues as we grow system placements and utilization in Japan.

21

Our research and development efforts are focused on the following: hardware and software product developments and enhancements of our NeuroStar Advanced Therapy System and clinical development relating to additional indications, which may include bipolar depression and post-traumatic stress disorder. We outsource the manufacture of components of our NeuroStar Advanced Therapy Systems that are produced to our specifications, and individual components are either shipped directly from our third-party contract manufacturers to our customers or consolidated into pallets at our Malvern, Pennsylvania facility prior to shipment. Final installation of these systems occurs at the customer site.

Our total revenues decreased by $6.8 million, or 41%, from $16.6 million for the three months ended June 30, 2019 to $9.7 million for the three months ended June 30, 2020 and by $8.1 million , or 28%, from $29.3 million for six months ended June 30, 2019 to $21.2 million for the six months ended June 30, 2020. For the three and six months ended June 30, 2020, our U.S. revenues were $9.3 million and $20.4 million compared to $15.9 million and $28.4 million for the three and six months ended June 30, 2019 , which represents a decrease of 42% and 28% period over period. We believe the decline was primarily attributable to the impact of the COVID-19 pandemic and related governmental responses. We incurred net losses of $7.8 million and $20.4 million for the three and six months ended June 30, 2020 compared to net losses of $7.1 million and $14.6 million for the three and six months ended June 30, 2019. We expect to continue to incur losses for the next several years as we invest in our commercial organization to support our planned sales growth and while continuing to invest in our pipeline indications. As of June 30, 2020, we had an accumulated deficit of $270.5 million.

COVID-19

We are closely monitoring the impact of the COVID-19 pandemic on all aspects of our business and geographies, including how it will impact the Company’s customers, supply chain, employees and other business partners. While we began to experience significant disruptions in March 2020 through the end of June 2020 from the COVID-19 pandemic, we are unable to predict the impact that the COVID-19 pandemic may have on our financial condition, results of operations and cash flows due to numerous uncertainties. These uncertainties include the scope, severity and duration of the pandemic, the actions taken to contain the pandemic or mitigate its impact and the direct and indirect economic effects of the pandemic and containment measures, among others. The outbreak of COVID-19 in many countries, including the United States, has significantly adversely impacted global economic activity and has contributed to significant volatility and negative pressure in financial markets. The global impact of the outbreak has been rapidly evolving and, as cases of COVID-19 have continued to be identified in additional countries, many countries, including the United States, have reacted by instituting quarantines, mandating business and school closures and restricting travel. Certain states and cities, including where our principal place of business is located, have also reacted by instituting quarantines, restrictions on travel, “shelter in place” rules, restrictions on types of business that may continue to operate, and/or restrictions on the types of construction projects that may continue. The Company cannot predict if additional states and cities will implement similar restrictions or when restrictions currently in place will expire. As a result, the COVID-19 pandemic is negatively impacting almost every industry directly or indirectly, including industries in which the Company operates. Further, the impacts of a potential worsening of global economic conditions and the continued disruptions to, and volatility in, the credit and financial markets, consumer spending as well as other unanticipated consequences remain unknown.

On April 8, 2020, the Company adopted a plan to reduce operating expenses in connection with the COVID-19 pandemic and the resulting economic downturn (the “Plan”). The Plan included a reduction in force across all functions within the Company (the “RIF”). The Company paid and recorded separation-related charges for the RIF equal to $2.1 million. The Company estimates that the Plan will produce net savings of approximately $18 million through December 31, 2020. Following the second quarter RIF, the Company’s workforce totaled 114 employees as of June 30, 2020.

The situation surrounding the COVID-19 pandemic remains fluid, and we are actively managing our response in collaboration with business partners and assessing potential impacts to our financial position and operating results, as well as potential adverse developments in our business. For further information regarding the impact of COVID-19 on the Company, see Part II, Item 1A titled “Risk Factors” of our Quarterly Report on Form 10-Q for the period ended March 31, 2020.

Components of Our Results of Operations

Revenues

To date, we have generated revenues primarily from the capital portion of our business and related sales and rentals of the NeuroStar Advanced Therapy System and the recurring revenues from our sale of treatment sessions in the United States.

NeuroStar Advanced Therapy System Revenues. NeuroStar Advanced Therapy System revenues consist primarily of sales or rentals of a capital component, including upgrades to the equipment attributable to the initial sale of the system. NeuroStar Advanced Therapy Systems can be purchased outright or on a rent-to-own basis by certain customers. We had an installed base of 1,122 and 976 active NeuroStar Advanced Therapy Systems as of June 30, 2020 and 2019, respectively.

22

Treatment Session Revenues. Treatment session revenues primarily include sales of NeuroStar Treatment Sessions and SenStar treatment links. The NeuroStar Treatment Sessions are access codes that are delivered electronically in the United States. The SenStar treatment links are disposable units containing single-use access codes that are sold and used outside the United States. Access codes are purchased separately by our customers, primarily on an as-needed basis, and are required by the NeuroStar Advanced Therapy System in order to deliver treatment sessions.

Other Revenues. Other revenues are derived primarily from service and repair and extended warranty contracts with our existing customers.

We refer you to the section titled “Critical Accounting Policies and Use of Estimates—Revenue Recognition” appearing in our Form 10-K filed with the SEC on March 3, 2020. We also refer you to “Note 3. Summary of Significant Accounting Policies.”

Cost of Revenues and Gross Margin

Cost of revenues primarily consists of the costs of components and products purchased from our third-party contract manufacturers of our NeuroStar Advanced Therapy Systems as well as the cost of treatment packs for individual treatment sessions. We use third-party contract manufacturing partners to produce the components for and assemble the completed NeuroStar Advanced Therapy Systems. Cost of revenues also includes costs related to personnel, royalties, warranty, shipping, and our operations and field service departments. We expect our cost of revenues to increase in absolute dollars as and to the extent our revenues grow.

Our gross profit is calculated by subtracting our cost of revenues from our revenues. We calculate our gross margin as our gross profit divided by our revenues. Our gross margin has been and will continue to be affected by a variety of factors, primarily product sales mix, pricing and third-party contract manufacturing costs. Our gross margins on revenues from sales of NeuroStar Advanced Therapy Systems are lower than our gross margins on revenues from sales of treatment sessions and, as a result, the sales mix between NeuroStar Advanced Therapy Systems and treatment sessions can affect the gross margin in any reporting period.

Sales and Marketing Expenses

Sales and marketing expenses consist of market research and commercial activities related to the sale of our NeuroStar Advanced Therapy Systems and treatment sessions and salaries and related benefits, sales commissions and share-based compensation for employees focused on these efforts. Other significant sales and marketing costs included conferences and trade shows, promotional and marketing activities, including direct and online marketing, practice support programs, television and radio media campaigns, travel and training expenses.

General and Administrative Expenses

General and administrative expenses consist primarily of personnel expenses, including salaries and related benefits, share-based compensation and travel expenses, for employees in executive, finance, information technology, legal and human resource functions. General and administrative expenses also include the cost of insurance, outside legal fees, accounting and other consulting services, audit fees from our independent registered public accounting firm, board of directors’ fees and other administrative costs, such as corporate facility costs, including rent, utilities, depreciation and maintenance not otherwise included in cost of revenues.

We anticipate that our general and administrative expenses will decrease in absolute dollars because of the actions taken by the company in response to the COVID-19 pandemic and the company’s reduction in force announced in April 2020.

Research and Development Expenses

Research and development expenses consist primarily of personnel expenses, including salaries and related benefits and share-based compensation for employees in clinical development, product development, regulatory and quality assurance functions, as well as expenses associated with outsourced professional scientific development services and costs of investigative sites and consultants that conduct our preclinical and clinical development programs. We typically use our employee, consultant and infrastructure resources across our research and development programs.

We plan to incur research and development expenses for the near future as we expect to continue our development of TMS Therapy for the treatment of additional patient populations and new indications, as well as for various hardware and software development projects.

Interest Expense

Interest expense consists of cash interest payable under our credit facility and non-cash interest attributable to the accrual of final payment fees and the amortization of deferred financing costs related to our indebtedness.

23

Other Expense (Income), Net

Other expense (income), net consists primarily of interest income earned on our money market account balances, and non-utilization fees paid to Oxford related to our decision not to borrow the Term C Loan.

Results of Operations

Comparison of the Three Months ended June 30, 2020 and 2019

|  | Three Months Ended June 30, |  |  | Increase / (Decrease) |
|  | 2020 |  |  | 2019 |  |  | Dollars |  |  | Percentage |
|  | (in thousands, except percentages) |
Revenues |  | $ | 9,741 |  |  | $ | 16,572 |  |  | $ | (6,831 | ) |  |  | -41 | %
Cost of revenues |  |  | 2,323 |  |  |  | 4,171 |  |  |  | (1,848 | ) |  |  | -44 | %
Gross Profit |  |  | 7,418 |  |  |  | 12,401 |  |  |  | (4,983 | ) |  |  | -40 | %
Gross Margin |  |  | 76.2 | % |  |  | 74.8 | % |  |  |  |  |  |  |  |
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales and marketing |  |  | 8,151 |  |  |  | 11,523 |  |  |  | (3,372 | ) |  |  | -29 | %
General and administrative |  |  | 4,010 |  |  |  | 4,261 |  |  |  | (251 | ) |  |  | -6 | %
Research and development |  |  | 2,116 |  |  |  | 3,224 |  |  |  | (1,108 | ) |  |  | -34 | %
Total operating expenses |  |  | 14,277 |  |  |  | 19,008 |  |  |  | (4,731 | ) |  |  | -25 | %
Loss from Operations |  |  | (6,859 | ) |  |  | (6,607 | ) |  |  | (252 | ) |  |  | -4 | %
Other (income) expense: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest expense |  |  | 986 |  |  |  | 931 |  |  |  | 55 |  |  |  | 6 | %
Other expense (income), net |  |  | (80 | ) |  |  | (444 | ) |  |  | 364 |  |  |  | -82 | %
Net Loss |  | $ | (7,765 | ) |  | $ | (7,094 | ) |  | $ | (671 | ) |  |  | -9 | %

|  | Revenues by Geography Three Months Ended June 30, |
|  | 2020 |  |  | 2019 |
|  | Amount |  |  | % of Revenues |  |  | Amount |  |  | % of Revenues |
|  | (in thousands, except percentages) |
United States |  | $ | 9,267 |  |  |  | 95 | % |  | $ | 15,890 |  |  |  | 96 | %
International |  |  | 474 |  |  |  | 5 | % |  |  | 682 |  |  |  | 4 | %
Total revenues |  | $ | 9,741 |  |  |  | 100 | % |  | $ | 16,572 |  |  |  | 100 | %

|  | U.S. Revenues by Product Category Three Months Ended June 30, |
|  | 2020 |  |  | 2019 |
|  | Amount |  |  | % of Revenues |  |  | Amount |  |  | % of Revenues |
|  | (in thousands, except percentages) |
NeuroStar Advanced Therapy System |  | $ | 2,338 |  |  |  | 25 | % |  | $ | 4,628 |  |  |  | 29 | %
Treatment sessions |  |  | 6,547 |  |  |  | 71 | % |  |  | 10,847 |  |  |  | 68 | %
Other |  |  | 382 |  |  |  | 4 | % |  |  | 415 |  |  |  | 3 | %
Total U.S. revenues |  | $ | 9,267 |  |  |  | 100 | % |  | $ | 15,890 |  |  |  | 100 | %

|  | United States NeuroStar Advanced Therapy System Revenues by Type Quarters ended June 30, |
|  | 2020 |  |  | 2019 |
|  | Amount |  |  | % of Revenues |  |  | Amount |  |  | % of Revenues |
|  | (in thousands, except percentages) |
NeuroStar Capital |  | $ | 2,224 |  |  |  | 95 | % |  | $ | 4,034 |  |  |  | 87 | %
Operating lease |  |  | 114 |  |  |  | 5 | % |  |  | 187 |  |  |  | 4 | %
Other |  |  | - |  |  |  | 0 | % |  |  | 407 |  |  |  | 9 | %
Total United States NeuroStar Advanced Therapy System revenues |  | $ | 2,338 |  |  |  | 100 | % |  | $ | 4,628 |  |  |  | 100 | %

24

Revenues

Total revenues decreased by $6.8 million, or 41%, from $16.6 million for the three months ended June 30, 2019 to $9.7 million for the three months ended June 30, 2020. The decrease was driven by a 42% and 30% reduction in U.S. and International revenue, respectively, primarily due to the impact of the COVID-19 pandemic.

NeuroStar Advanced Therapy System revenues represented 25% and 29% of U.S. revenues for the three months ended June 30, 2020 and 2019, respectively. U.S. NeuroStar Advanced Therapy System revenue for the second quarter of 2020 was $2.3 million, a decrease of 50% versus second quarter 2019 revenue of $4.6 million. The decrease was primarily driven by lower blended NeuroStar Capital System average selling prices due to higher mix of sales type leases during the quarter, as well as lower other revenue related to fewer HP Coil upgrades sold in the second quarter of 2020. In the quarter, the Company sold 61 systems, equal to the prior year quarter.

As of June 30, 2020, we had an installed base of 1,122 active Systems in the United States. This represents an increase of 126 units, or 13%, over the active installed base as of June 30, 2019.

Treatment Session revenues in the United States represented 71% and 68% of total revenues in the United States for the three months ended June 30, 2020 and 2019, respectively, and decreased by 40% from $10.8 million for the three months ended June 30, 2019 to $6.5 million for the three months ended June 30, 2020. The decrease was primarily driven by a decline in average revenue per active system, largely driven by a reduction in per click Treatment Session volume during March which we believe was caused by the impact from COVID-19.

Cost of Revenues and Gross Margin

Cost of revenues decreased by $1.8 million or 44% from $4.2 million for the three months ended June 30, 2019 to $2.3 million for the three months ended June 30, 2020 when compared to the three months ended June 30, 2019 Gross margin increased from 74.8% for the three months ended June 30, 2019 to 76.2% for the three months ended June 30, 2020. The increase was primarily a result of a change in the product mix of revenues versus the prior year as well as reduced personnel supporting our installation efforts.

Sales and Marketing Expenses

Sales and marketing expenses decreased by $3.4 million, or 29%, from $11.5 million for the three months ended June 30, 2019 to $8.2 million for the three months ended June 30, 2020. The decrease was primarily due to reduced marketing expenses, including trade shows and advertising, travel expenses and personnel costs.

General and Administrative Expenses

General and administrative expenses decreased by $0.3 million, or 6%, from $4.3 million for the three months ended June 30, 2019 to $4.0 million for the three months ended June 30, 2020. The decrease was primarily due to lower personnel and other expenses.

Research and Development Expenses

Research and development expenses decreased $1.1 million, or 34%, from $3.2 million for the three months ended June 30, 2019 to $2.1 million for the three months ended June 30, 2020. The decrease was primarily due to reduced product development, personnel and travel expenses.

Interest Expense

Interest expense increased $0.1 million, or 6% from $0.9 million for the three months ended June 30, 2019 to $1.0 million for the three months ended June 30, 2020. We also refer you to “Note 12. DEBT.”

Other Expense (Income), Net

Other expense (income), net decreased by $0.4 million, from $(0.4) million for the three months ended June 30, 2019 to $(0.1) million for the three months ended June 30, 2020, primarily as a result of decreased interest income earned on the Company’s money market accounts.

Liquidity and Capital Resources

Overview

On July 2, 2018, we closed our IPO, in which we issued and sold 6.325 million shares of our common stock, which included shares sold pursuant to an option granted to the underwriters to purchase additional shares, at a public offering price of $17.00 per share. We received net proceeds of $96.5 million after deducting underwriting discounts, commissions, and other offering expenses paid by us. Our common stock is listed on the Nasdaq Global Market under the trading symbol “STIM.”

25

As of June 30, 2020, we had cash and cash equivalents of $54.0 million and an accumulated deficit of $270.5 million, compared to cash and cash equivalents of $75.7 million and an accumulated deficit of $250.1 million as of December 31, 2019. We incurred negative cash flows from operating activities of $23.1 million and $16.4 million for the six months ended June 30, 2020 and June 30, 2019, respectively. We have incurred operating losses since our inception, and we anticipate that our operating losses will continue in the near term as we seek to expand our sales and marketing initiatives to support our growth in existing and new markets, invest funds in additional research and development activities and utilize cash for other corporate purposes. Our primary sources of capital to date have been from our IPO, private placements of our convertible preferred securities, borrowings under our credit facilities and sales of our products. As of June 30, 2020, the Company had $35.0 million of borrowings outstanding under its credit facility, which has a final matur ity in February 202 5. As discussed in Note 12, the outstanding balance under the credit facility is classified as a current liability as of June 30, 2020 Management believes that the Company’s cash and cash equivalents and anticipated revenues from sales of its products are sufficient to fund the Company’s operations (including the potential repayment of the credit facility if a waiver or amendment is not obtained) for at least 12 months from the issuance of these financial statements.

We cannot predict our revenues and expenses in the short term as a result of the COVID-19 pandemic and related governmental responses. We also incur additional costs as a public company. Based on our current business plan, we believe that our cash and cash equivalents and anticipated revenues from sales of our products will be sufficient to meet our cash requirements through August 5, 2021. However, if these sources are insufficient to satisfy our liquidity requirements, we may seek to sell additional common or preferred equity or debt securities or enter into a new credit facility or another form of third-party funding or seek other debt financing. If we raise additional funds by issuing equity or equity-linked securities, our stockholders would experience dilution and any new equity securities could have rights, preferences and privileges superior to those of holders of our common stock. Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt. We cannot be assured that additional equity, equity-linked or debt financing will be available on terms favorable to us or our stockholders, or at all. It is also possible that we may allocate significant amounts of capital towards products or technologies for which market demand is lower than expected and, as a result, abandon such efforts. If we are unable to maintain our current financing or obtain adequate additional financing when we require it, or if we obtain financing on terms which are not favorable to us, or if we expend capital on products or technologies that are unsuccessful, our ability to continue to support our business growth and to respond to business challenges could be significantly limited, or we may be required to delay the development, commercialization and marketing of our products.

Our current and future funding requirements will depend on many factors, including:

| • | the impact of COVID-19 and related governmental responses;

| • | our ability to achieve revenue growth and improve operating margins;

| • | compliance with the terms and conditions, including covenants, set forth in our credit facility;

| • | the cost of expanding our operations and offerings, including our sales and marketing efforts;

| • | our ability to improve or maintain coverage and reimbursement arrangements with domestic third-party and government payors, particularly in Japan;

| • | our rate of progress in establishing coverage and reimbursement arrangements from international commercial third-party and government payors;

| • | our rate of progress in, and cost of the sales and marketing activities associated with, establishing adoption of our products and maintaining or improving our sales to our current customers;

| • | the cost of research and development activities, including research and development relating to additional indications, which may include bipolar depression and PTSD;

| • | the effect of competing technological and market developments;

| • | costs related to international expansion; and

| • | the potential cost of and delays in product development as a result of any regulatory oversight applicable to our products.

Cash Flows

The following table sets forth a summary of our cash flows for the six months ended June 30, 2020 and 2019

|  | Six Months Ended June 30, |
|  | 2020 |  |  | 2019 |
|  | (in thousands) |
Net Cash Used in Operating Activities |  | $ | (23,131 | ) |  | $ | (16,418 | )
Net Cash Used in Investing Activities |  |  | (484 | ) |  |  | (398 | )
Net Cash Provided by Financing Activities |  |  | 1,903 |  |  |  | 1,877 |
Net Decrease in Cash and Cash Equivalents |  | $ | (21,712 | ) |  | $ | (14,939 | )

26

Net Cash Used in Operating Activities

Net cash used in operating activities for the six months ended June 30, 2020 was $23.1 million, consisting primarily of a net loss of $20.4 million and a decrease in net operating liabilities of $6.8 million, partially offset by non-cash charges of $4.1 million. The decrease in net operating liabilities was primarily due to decreases in accounts payable and accrued expenses as a result of timing and the 2020 payments of 2019 incentive compensation and commissions accrued as of December 31, 2019. Non-cash charges consisted of loss on debt extinguishment, depreciation and amortization, non-cash interest expense, share-based compensation, and the cost of rental units purchased by customers.

Net cash used in operating activities for the six months ended June 30, 2019 was $16.4 million, consisting primarily of a net loss of $14.6 million and a decrease in net operating liabilities of $4.2 million, partially offset by non-cash charges of $2.4 million. Non-cash charges consisted of depreciation and amortization, non-cash interest expense, share-based compensation and the cost of rental units purchased by customers.

Net Cash Used in Investing Activities

Net cash used in investing activities for the six months ended June 30, 2020 and the six months ended June 30, 2019 was $0.5 million and $0.4 million respectively, and was in each case attributable to purchases of property and equipment and capitalized software costs.

Net Cash Provided by Financing Activities

Net cash provided by financing activities for the six months ended June 30, 2020 was $1.9 million and consisted of additional proceeds from our loan refinance and cash proceeds related to stock option exercises. Net cash provided by financing activities for the six months ended June 30, 2019 was $1.9 million, consisting of cash proceeds related to stock option exercises.

Indebtedness

Solar Credit Facility

On March 2, 2020, the “Company entered into a loan and security agreement with Solar Capital Ltd. (“Solar”), as collateral agent, and other lenders defined in the agreement, for a credit facility (the “Solar Facility”) that replaced the Company’s previous $35.0 million credit facility with Oxford Finance LLC (“Oxford”, and such facility, the “Oxford Facility”).

The Solar Facility permits the Company to borrow up to an aggregate amount of $50.0 million in two tranches of term loans, a “Term A Loan” and “Term B Loan.” On March 2, 2020, the Company borrowed an aggregate amount of $35.0 million, which was the aggregate amount available under the Term A Loan portion of the Solar Facility. The Term A Loan portion of the Solar Facility matures, and all amounts borrowed thereunder are due, on February 28, 2025. Under the Term B Loan portion of the Solar Facility, the Company is permitted to borrow, at its election, up to an aggregate amount of $15.0 million, (i) upon the Company achieving a specified amount of trailing twelve months net product revenue, and (ii) assuming there has been no event of default under the Solar Facility prior to such election. Once the net product revenue condition has been satisfied, the Company may only make an election to borrow under the Term B Loan portion of the Solar Facility until the earlier of (a) December 15, 2021, (b) 30 days following achievement of the net product revenue condition or (c) the occurrence of an event of default.

Each of the Term A Loan and Term B Loan accrue interest from the date of borrowing through the date of repayment at a floating per annum rate of interest, which resets monthly and is equal to 7.65% plus the greater of (a) 1.66% or (b) the rate per annum rate published by the Intercontinental Exchange Benchmark Administration Ltd. The Term A Loan and the Term B Loan both include an interest-only period through March 1, 2022, after which time the Company will be required to make monthly payments of principal and interest. Monthly principal payments are to be paid in equal amounts on a pro rata basis to lenders. At the Company’s election, the interest only period may be extended through February 2023 if the Company satisfies a minimum net product revenue covenant through March 1, 2022 and no event of default shall have occurred.

In addition to the principal and interest payments due under the Solar Facility, the Company is required to pay a final payment fee to Solar due upon the earlier of prepayment, acceleration or the maturity date of the Term A Loan or Term B Loan portion of the Solar Facility equal to 5.50% of the principal amount of the term loans actually funded. The Company is accruing the final payment fees using the effective interest rate, with a charge to non-cash interest expense, over the term of borrowing. If the Company prepays either the of the Term A Loan or Term B Loan prior to their respective scheduled maturities, the Company will also be required to pay prepayment fees to Solar equal to 3% of the principal amount of such term loan then-prepaid if prepaid on or before the first anniversary of funding, 2% of the principal amount of such term loan then-prepaid if prepaid after the first anniversary and on or before the second anniversary of funding, or 1% of the principal amount of such term loan then-prepaid if prepaid after the second anniversary of funding of the principal amounts borrowed.

27

The Company is also required to pay Solar an exit fee upon the occurrence, prior to March 2, 2030, of (a) any liquidation, dissolution or winding up of the Company, (b) transaction that results in a person obtaining control over the Company, (c) the Company achieving $100 million in trailing twelve month net product revenue or (d) the Company achieving $125 million in trailing twelve month net product revenue. The exit fee for liquidation, dissolution, winding up or change of control of the Company is equal to 4.50% of the principal amount of the term loans actually funded. The exit fee for achieving either $100 million or $125 million in trailing twelve-month net product revenue is equal to 2.25% of the principal amount of the term loans actually funded or, if both net product revenue milestones are achieved, 4.50% of the principal amount of the term loans actually funded. The exit fee is capped at 4.50% of the principal amount of the term loans actually funded.

The Company’s obligations under the credit facility are secured by a first priority security interest in substantially all of its assets, including its intellectual property. The loan and security agreement requires the Company to comply with certain financial covenants as well as customary affirmative and negative covenants.

The Solar Facility contains events of default, including, without limitation, events of default upon: (i) failure to make payment pursuant to the terms of the agreement; (ii) violation of covenants; (iii) material adverse changes to the Company’s business; (iv) attachment or levy on the Company’s assets or judicial restraint on its business; (v) insolvency; (vi) material cross-defaults; (vii) significant judgments, orders or decrees for payments by the Company not covered by insurance; (viii) incorrectness of representations and warranties; (ix) incurrence of subordinated debt; (x) a termination or breach of a guaranty; (xi) revocation of governmental approvals necessary for the Company to conduct its business; and (xii) failure by the Company to maintain a valid and perfected lien on the collateral securing the borrowing.

As of June 30, 2020, the Company is in compliance with all covenants in the Solar Facility.

The Solar Facility includes a financial covenant requiring the attainment of a minimum trailing net revenue amount beginning on December 31, 2020. Based upon the Company’s projected revenues for the rest of 2020, the Company believes that it is probable that this minimum revenue covenant will not be achieved. The Company is in discussions with the lenders for a potential covenant waiver or amendment, however, no formal agreement has been executed. The Solar Facility also includes subjective acceleration clauses which permit the lenders to accelerate the maturity date under certain circumstances, including, but not limited to, material adverse effects on a Company’s financial status or otherwise. In accordance with FASB ASC 470 because the Solar Facility contains subjective acceleration clauses and the assessment that it is probable that the revenue covenant will not be met as of December 31, 2020, the outstanding principal under the Solar Facility is classified as a current liability in the accompanying balance sheet as of June 30, 2020.

Oxford Credit Facility

Prior to March 2020, the Company had a $35.0 million credit facility in place with Oxford, which it entered into in March 2017 and that allowed it to borrow up to $35.0 million in three tranches of term loans: a Term A Loan in the amount of $25 million, which was drawn immediately upon closing in March 2017, a Term B Loan in the amount of $5.0 million, which was drawn down in December 2017, and a Term C Loan in the amount of $5.0 million which was never drawn down. Each term loan accrued interest from the date of borrowing through the date of repayment at a floating per annum rate of interest, which reset monthly and was equal to the greater of (a) 8.15% or (b) the 30 day U.S. LIBOR on the last business day of the month plus 7.38%. This facility featured an interest-only period on all tranches through March 2019.

In addition to principal and interest payments due under the $35.0 million Oxford credit facility, the Company was required to make final payment fees to Oxford upon the earlier of prepayment or maturity and equal to 8.5% and 7.5% of the principal amounts of the Term A and Term B Loans, respectively. The Company accrued final payment fees using the effective interest rate, with a charge to non-cash interest expense, over the term of borrowing and until its entry into the Solar credit facility in March 2020, at which time the Company paid Oxford $2.5 million in satisfaction of all final payment fee liabilities due under the Oxford credit facility.

The Company evaluated whether the Solar credit facility entered into in March 2020 represented a debt modification or extinguishment in accordance with ASC 470-50, Debt—Modifications and Extinguishments and determined that the existing debt was extinguished as a result of the full repayment of the existing facility and concurrent issuance of a new credit facility with a new lender. The unamortized balance of the Company’s combined debt discount and deferred issuance costs of $0.6 million related to the Oxford facility were accounted for as a loss on extinguishment of debt.

Cash and Non-Cash Interest Expense

For the three months ended June 30, 2020, we recognized interest expense of $1.0 million, of which $0.8 million was cash and $0.2 million was non-cash interest expense related to the amortization of deferred financing costs. For the three months ended June 30, 2019, we recognized interest expense of $0.9 million, of which $0.7 million was cash and $0.2 million was non-cash interest expense related to the amortization of deferred financing costs and accrual of final payment fees.

28

Off-Balance Sheet Arrangements

We do not maintain any off-balance sheet arrangements, partnerships or other relationships with unconsolidated entities, often referred to as structured finance or special-purpose entities, which are established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

Commitments and Contractual Obligations

As of June 30, 2020, there was one significant change to our commitments and future minimum contractual obligations as set forth in our Form 10-K, filed with the SEC on March 3, 2020. We refer you to “Note 12. Debt” in the financial statements included in this Quarterly Report on Form 10-Q for information regarding our new debt agreement.

JOBS Act Accounting Election

We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act, and are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, or Securities Act, for complying with new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to avail ourselves of this exemption from complying with new or revised accounting standards and, therefore, will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. Section 107 of the JOBS Act provides that we can elect to opt out of the extended transition period at any time, which election is irrevocable.

Subject to certain conditions, as an emerging growth company, we may rely on certain of these exemptions, including without limitation (i) providing an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an emerging growth company until the earlier of (a) the last day of the fiscal year in which we have total annual gross revenue of $1.07 billion or more; (b) the last day of the fiscal year following the fifth anniversary of the date of the completion of this offering; (c) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous six years; or (d) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.

Recent Accounting Pronouncements

We refer you to “Note 3. Summary of Significant Accounting Policies” and “Note 4. Recent Accounting Pronouncements” in “Notes to Interim Financial Statements” located in “Part I – FINANCIAL INFORMATION, Item 1. Financial Statements”.

29

Item 3. | Quantitative and Qualitative Disclosures About Market Risk.

Our cash is held on deposit in demand accounts at a large financial institution in amounts in excess of the Federal Deposit Insurance Corporation, or FDIC, insurance coverage limit of $250,000 per depositor, per FDIC-insured bank, per ownership category. We have reviewed the financial statements of this institution and believe it has sufficient assets and liquidity to conduct its operations in the ordinary course of business with little or no credit risk to us.

Financial instruments that potentially subject us to concentrations of credit risk principally consist of cash equivalents and accounts receivable. We limit our credit risk associated with cash equivalents by placing investments in highly-rated money market funds. We limit our credit risk with respect to accounts receivable by performing credit evaluations when deemed necessary, but we do not require collateral to secure amounts owed to us by our customers.

As discussed above in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources - Indebtedness” section of this Quarterly Report on Form 10-Q, our credit facility bears interest at 7.65% plus the greater of (a) 1.66% or (b) the rate per annum rate published by the Intercontinental Exchange Benchmark Administration Ltd. As a result, we are exposed to risks from changes in interest rates.

Inflationary factors, such as increases in our cost of revenues and operating expenses, may adversely affect our operating results. Although we do not believe inflation has had a material impact on our financial condition, results of operations or cash flows to date, a high rate of inflation in the future may have an adverse effect on our ability to maintain and increase our gross margin or decrease our operating expenses as a percentage of our revenues if our selling prices of our products do not increase as much or more than our costs increase.

We do not currently have any exposure to foreign currency fluctuations and do not engage in any hedging activities as part of our normal course of business.

COVID-19

During the first and second quarters of 2020, the Company experienced a material impact to revenue, particularly with regards to U.S. treatment session revenues. As noted in the Company’s April 8, 2020 press release, the Company expects that capital equipment sales and treatment session revenues will be materially impacted by this pandemic as customers are deferring capital purchase decisions, and new patient treatment starts and system utilization have declined compared to pre-COVID-19 projections.

The Company previously withdrew full year 2020 guidance on April 8, 2020. At this date, the Company is currently unable to estimate the specific duration or scale of the impact of the COVID-19 pandemic on its financial and operating results.

Item 4. | Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or Exchange Act, refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, our management, with the participation of our Principal Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Principal Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2020.

Management’s Report on Internal Control Over Financial Reporting

Internal control over financial reporting refers to the process designed by, or under the supervision of, our Principal Executive Officer and Chief Financial Officer, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that: (1) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a material effect on the financial statements.

30

Internal control over financial reporting may not prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are achieved. Further, the design of a control system must be balanced against resource constraints, and therefore the benefits of controls must be considered relative to their costs. Given the inherent limitations in all systems of controls, no evaluation of controls can provide absolute assurance all control issues and instances of fraud, if any, within a company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions or the degree of compliance with policies or procedures may deteriorate. Accordingly, given the inherent limitations in a cost-effective system of internal control, financial statement misstatements due to error or fraud may occur and may not be detected. Our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance of achieving their objectives. We conduct periodic evaluations of our systems of controls to enhance, where necessary, our control policies and procedures.

Management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including our Principal Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting. Management has used the framework set forth in the report entitled “Internal Control—Integrated Framework (2013)” published by the Committee of Sponsoring Organizations of the Treadway Commission to evaluate the effectiveness of our internal control over financial reporting. Based on its evaluation, management has concluded that our internal control over financial reporting was effective as of June 30, 2020 at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

During the quarter ended June 30, 2020, there were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) which materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

31

PART II—OTHER INFORMATION

Item 1. | Legal Proceedings.

We are subject from time to time to various claims and legal actions arising during the ordinary course of our business. We believe that there are currently no claims or legal actions that would reasonably be expected to have a material adverse effect on our results of operations, financial condition, or cash flows.

Item 1A. | Risk Factors.

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 3, 2020, and our Quarterly Report on Form 10-Q for the fiscal quarter ended March, 31, 2020, filed with the SEC on May 5, 2020. With the exception of the following, there have been no material changes in reported risk factors from the information reported in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2020.

The COVID-19 pandemic has had, and we expect will continue to have, an adverse effect on our business, results of operations, financial condition and cash flows, the nature and extent of which are highly uncertain and unpredictable.

Our operations and interactions with healthcare systems, providers and patients expose us to risks associated with public health crises, including epidemics and pandemics such as COVID-19. In particular, the continuing global spread of COVID-19, including corresponding preventative and precautionary measures that we and other businesses, communities and governments are taking to mitigate the spread of the disease, has led to unprecedented restrictions on, disruptions in, and other related impacts on business and personal activities. Further, in addition to travel restrictions put in place beginning in early 2020, countries, states and governments may continue to close borders, impose prolonged quarantines or other restrictions and requirements on travel, and further limit our ability to conduct business in-person as we did prior to COVID-19, requiring businesses, including our business, to use alternative methods of communication. It is likely the COVID-19 pandemic will cause an economic slowdown of potentially extended duration, and it is possible that it could cause a global recession.

Together with the preventative and precautionary measures being taken, as well as the corresponding need to adapt to new and different methods of communication and conducting business, COVID-19 is having, and will likely continue to have, an adverse impact on significant aspects of our company and business, including on demand for and supply of our products, operations, supply chains and distribution systems, our ability to research and develop and bring to market new products and services, and our ability to generate cash flow, and may have an adverse impact on our ability to access capital. Although we consider treatment by NeuroStar to be a medical necessity, our experience since March 2020 demonstrates that quarantine and similar public health orders cause a material reduction in sales of NeuroStar and in NeuroStar utilization. It is not possible to predict the possibility, locations or timing of such orders but if such orders are re-imposed regionally or nationally in the United States or Japan or if unemployment or loss of insurance coverage continues or worsens from the present situation, our business, cash flows, financial condition and results of operations will continue to be negatively affected.

A significant number of our suppliers, vendors, distributors and manufacturing facilities have been adversely affected by the COVID-19 pandemic, including by adversely impacting the ability of their employees to get to their places of work and maintain the continuity of their on-site operations. These impacts could impair our ability to move our products through distribution channels to end customers, and any such delay or shortage in the supply of components or materials may result in our inability to satisfy demand for our products in a timely manner or at all, which could harm our reputation, future sales and profitability.

In addition, COVID-19 has impacted and may further impact the global economy and capital markets, including by negatively impacting demand for our products, access to capital markets, foreign currency exchange rates, and interest rates, each of which may adversely impact our business and liquidity. We could experience loss of sales and profits due to delayed payments or insolvency of healthcare professionals, hospitals and other customers, suppliers and vendors facing liquidity issues.

Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds.

Recent Issuances of Unregistered Securities

None.

Item 3. | Defaults Upon Senior Securities.

Not applicable.

Item 4. | Mine Safety Disclosures.

Not applicable.

Item 5. | Other Information.

None.

32

Item 6. | Exhibits.

The following is a list of exhibits filed as part of this Quarterly Report on Form 10-Q. Where so indicated, exhibits that were previously filed are incorporated by reference. For exhibits incorporated by reference, the location of the exhibit in the previous filing is indicated.

Exhibit Number |  | Description
10.1 |  | Employment Agreement, dated July 14, 2020, by and between Neuronetics, Inc. and Keith J. Sullivan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on July 17, 2020).
10.2* |  | Form of Neuronetics, Inc. Performance Restricted Stock Unit Grant Notice and Award Agreement under Nasdaq Listing Rule 5635(c)(4).
10.3* |  | Form of Neuronetics, Inc. Performance Restricted Stock Unit Grant Notice and Award Agreement under the 2018 Equity Incentive Plan.
10.4* |  | Form of Neuronetics, Inc. Restricted Stock Unit Grant Notice and Award Agreement under Nasdaq Listing Rule 5635(c)(4).
10.5* |  | Form of Neuronetics, Inc. Stock Option Grant Notice and Agreement (Nonstatutory Stock Option) under Nasdaq Listing Rule 5635(c)(4).
10.6* |  | Performance Restricted Stock Unit Grant Notice and Award Agreement, dated July 14, 2020, by and between Neuronetics, Inc. and Keith J. Sullivan.
10.7* |  | Restricted Stock Unit Grant Notice and Award Agreement, dated July 14, 2020, by and between Neuronetics, Inc. and Keith J. Sullivan.
10.8* |  | Stock Option Grant Notice and Agreement (Nonstatutory Stock Option), dated July 14, 2020, by and between Neuronetics, Inc. and Keith J. Sullivan.
31.1* |  | Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2* |  | Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1** |  | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2** |  | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS |  | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because iXBRL tags are embedded within the Inline XBRL document.
101.SCH |  | Inline XBRL Taxonomy Extension Schema Document
101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 |  | Cover Page Interactive Data File (Formatted as Inline XBRL and contained Exhibit 101).

* | Filed herewith.

** | This certification is being furnished solely to accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C Section 1350 and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

33

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| NEURONETICS, INC. (Registrant)
Date: August 4, 2020 | By: |  | /s/ Keith J. Sullivan
| Name: |  | Keith J. Sullivan
| Title: |  | President and Chief Executive Officer
|  |  | (Principal Executive Officer)
Date: August 4, 2020 | By: |  | /s/ Stephen Furlong
| Name: |  | Stephen Furlong
| Title: |  | VP, Finance and Chief Financial Officer
|  |  | (Principal Financial and Accounting Officer)

34